Hubbry Logo
AstraZenecaAstraZenecaMain
Open search
AstraZeneca
Community hub
AstraZeneca
logo
8 pages, 0 posts
0 subscribers
Be the first to start a discussion here.
Be the first to start a discussion here.
AstraZeneca
AstraZeneca
AstraZeneca
View on Wikipedia
from Wikipedia

AstraZeneca plc (/ˌæstrəˈzɛnəkə/) (AZ) is a British-Swedish[3][4][5] multinational pharmaceutical and biotechnology company with its headquarters at the Cambridge Biomedical Campus in Cambridge, UK. It has a portfolio of products for major diseases in areas including oncology, cardiovascular, gastrointestinal, infection, neuroscience, respiratory, and inflammation.

Key Information

The company was founded in 1999 through the merger of the Swedish Astra AB and the British Zeneca Group[6][7] (itself formed by the demerger of the pharmaceutical operations of Imperial Chemical Industries in 1993). Its portfolio includes primary and speciality care, coverage for rare diseases, and a robust global presence across various regions.[8] Since the merger it has been among the world's largest pharmaceutical companies and has made numerous corporate acquisitions, including Cambridge Antibody Technology (in 2006), MedImmune (in 2007), Spirogen (in 2013) and Definiens (by MedImmune in 2014). It has its research and development concentrated in three strategic centres: Cambridge, UK; Gothenburg, Sweden;[9][10] and Gaithersburg, Maryland, US.[11]

AstraZeneca traces its earliest corporate history to 1913, when Astra AB was formed by a large group of doctors and apothecaries in Södertälje. Throughout the twentieth century, it grew into the largest pharmaceutical company in Sweden. Its British counterpart, Zeneca PLC was formed in 1993 when ICI divested its pharmaceuticals businesses; Astra AB and Zeneca PLC merged six years later, with the chosen headquarters in the United Kingdom.[12]

AstraZeneca's primary listing is on the London Stock Exchange and is a constituent of the FTSE 100 Index; it also has a secondary listing on Nasdaq Stockholm. It is also listed on the American Nasdaq and is a Nasdaq-100 company. AstraZeneca has one of the highest market capitalisations of pharmaceutical companies worldwide.[13]

History

[edit]

Astra AB was founded in 1913 in Södertälje, Sweden, by 400 doctors and apothecaries.[14] In 1993 the British chemicals company ICI (established from four British chemical companies) demerged its pharmaceuticals businesses and its agrochemicals and specialities businesses, to form Zeneca Group PLC.[15] Finally, in 1999 Astra and Zeneca Group merged to form AstraZeneca plc, with its headquarters in London.[15] In 1999, AstraZeneca identified a new location for the company's US base, the "Fairfax-plus" site in North Wilmington, Delaware.[16]

2000–2006

[edit]

In September 2002, its drug Iressa (gefitinib) was approved in Japan as monotherapy for non-small cell lung cancer.[17] On 3 January 2004 Dr Robert Nolan, a former director of AstraZeneca, formed the management team of ZI Medical.[18]

In December 2005, the company acquired KuDOS Pharmaceuticals, a UK biotech company, for £120 million.[19] and entered into an anti-cancer collaboration agreement with Astex.[20] That same year, the firm also became a Diamond Member of the Pennsylvania Bio commerce organisation.[21]

In May 2006, following a collaborative relationship begun in 2004, AstraZeneca acquired Cambridge Antibody Technology for £702 million.[22]

2007–2012: The patent cliff and subsequent acquisitions

[edit]

In February 2007, AstraZeneca agreed to buy Arrow Therapeutics, a company focused on the discovery and development of anti-viral therapies, for US$150 million.[23] AstraZeneca's pipeline, and "patent cliff", was the subject of much speculation in April 2007 leading to pipeline-boosting collaboration and acquisition activities.[24] A few days later AstraZeneca acquired US company MedImmune for about US$15.2 billion to gain flu vaccines and an anti-viral treatment for infants;[25] AstraZeneca subsequently consolidated all of its biologics operations into a dedicated biologics division called MedImmune.[26]

In December 2009, AstraZeneca acquired Novexel Corp, an antibiotics discovery company formed in 2004 as a spin-off of the Sanofi-Aventis anti-infectives division. Astra acquired the experimental antibiotic NXL-104 (CEF104) (CAZ-AVI) through this acquisition.[27][28]

In December 2011, AstraZeneca acquired Guangdong BeiKang Pharmaceutical Company, a Chinese generics business.[29]

In February 2012, AstraZeneca and Amgen announced a collaboration on treatments for inflammatory diseases.[30] Then in April 2012, AstraZeneca acquired Ardea Biosciences, another biotechnology company, for $1.26 billion.[31] In June 2012, AstraZeneca and Bristol Myers Squibb announced a two-stage deal for the joint acquisition of the biotechnology company Amylin Pharmaceuticals.[32][33] It was agreed that Bristol Myers Squibb would acquire Amylin for $5.3 billion in cash and the assumption of $1.7 billion in debt, with AstraZeneca then paying $3.4 billion in cash to Bristol Myers Squibb, and Amylin being folded into an existing diabetes joint venture between AstraZeneca and Bristol Myers Squibb.[33]

2013 restructuring and beyond

[edit]

2013

[edit]

In March 2013, AstraZeneca announced plans for a major corporate restructuring, including the closure of its research and development activities at Alderley Park in Cheshire and Loughborough in the UK and at Lund in Sweden, investment of $500 million in the construction of a new research and development facility in Cambridge and the concentration of R&D in three locations: Cambridge, Gaithersburg, Maryland (location of MedImmune, where it will work on biotech drugs), and Gothenburg in Sweden,[9][10] for research on traditional chemical drugs.[11] AstraZeneca also announced that it would move its corporate headquarters from London to Cambridge in 2016.[34][35] That announcement included the announcement that it would cut 1,600 jobs; three days later it announced it would cut an additional 2,300 jobs.[36][37] It also announced that it would focus on three therapeutic areas: Respiratory Inflammation & Autoimmunity, Cardiovascular & Metabolic Disease, and Oncology.[38] In October 2013, AstraZeneca announced it would acquire biotech oncology company Spirogen for around US$440 million.[39]

2014

[edit]

On 19 May 2014, AstraZeneca rejected a "final offer" from Pfizer of £55 per share, which valued the company at £69.4 billion (US$117 billion). The companies had been meeting since January 2014. If the takeover had proceeded, Pfizer would have become the world's biggest drug maker. The transaction would also have been the biggest foreign takeover of a British company. Many in Britain, including politicians and scientists, had opposed the deal.[40] In July 2014 the company entered into a deal with Almirall to acquire its subsidiary Almirall Sofotec and its lung treatments including the COPD drug, Eklira. The US$2.1 billion deal included an allocation of US$1.2 billion for development in the respiratory franchise, one of AstraZeneca's three target therapeutic areas announced the year before. In August 2014 the company announced it had entered into a three-year collaboration with Mitsubishi Tanabe Pharma on diabetic nephropathy.[41]

In September 2014, the company joined forces with Eli Lilly in developing and commercialising its candidate BACE inhibitor – AZD3292 – used for the treatment of Alzheimer's disease; this deal was projected to yield up to US$500 million AstraZeneca.[42] In November 2014, the firm's biologics R&D operation, MedImmune, agreed to acquire Definiens for more than US$150 million. It also began a Phase I/II trial collaboration with Pharmacyclics and Janssen Biotech investigating combination treatments.[43] Also in November, AstraZeneca agreed to sell its lipodystrophy treatment business to Aegerion Pharmaceuticals for more than US$325 million.[44] In December, the company received accelerated FDA approval for Olaparib in the treatment of women with advanced ovarian cancer who have a BRCA genetic mutation. A major criterion governing the drugs approval was, on average, its ability to shrink tumours in patients for 7.9 months.[45]

2015

[edit]

In February 2015, AstraZeneca announced it would acquire the US and Canadian rights to Actavis's branded respiratory drug business for an initial sum of US$600 million.[46] That same month, the company announced a partnership with Orca Pharmaceuticals to develop retinoic acid-related orphan nuclear receptor gamma inhibitors for use in the treatment of several autoimmune diseases, which could generate up to US$122.5 million for Orca.[47] The company also announced its plan to spend US$40 million creating a new subsidiary focused on small molecule anti-infectives – primarily in the research of the gyrase inhibitor, AZD0914, which was then in Phase II testing for the treatment of gonorrhea.[48] The company underwrote twenty out of thirty-two seats of a new Cambridge– Gothenburg service by Sun-Air of Scandinavia.[49]

In March, the company stated that it would co-commercialise naloxegol along with Daiichi Sankyo in a deal worth up to US$825 million.[50] In April, the firm announced a number of collaborations worth an estimated US$1.8 billion; first, to develop and commercialise MEDI4736, with Celgene, for use against non-Hodgkin’s lymphoma, myelodysplastic syndromes, and multiple myeloma with AstraZeneca receiving US$450 million. The second of two deals is an agreement to study a combination treatment of MEDI4736 and Innate Pharma's Phase II anti-NKG2A antibody IPH2201 for up to US$1.275 billion. The company's MedImmune arm also launched collaborative clinical trials with Juno Therapeutics, investigating combination treatments for cancer;[51] these trials involved combinations of MEDI4736 and one of Juno Therapeutics' CD19 directed chimeric antigen receptor T-cell candidates.[52] In June, the company revealed a partnership with Eolas Therapeutics on the Eolas Orexin-1 Receptor Antagonist (EORA) program for smoking cessation and other treatments.[53] In July, AstraZeneca announced the sale of its rights to Entocort (budesonide) to Tillotts Pharma for $215 million.[54] In July, Genzyme announced it would acquire the rare cancer drug Caprelsa (vandetanib) from AstraZeneca for up to US$300 million.[55]

In August, the company announced it had acquired the global rights to develop and commercialise Heptares Therapeutics' drug candidate HTL-1071, which focuses on blocking the adenosine A2A receptor, in a deal worth up to US$510 million.[56] That same month, the company's MedImmune subsidiary acquired exclusive rights to Inovio Pharmaceuticals' INO-3112 immunotherapy under an agreement which could net more than US$727.5 million for Inovio. INO-3112 targets Human papillomavirus types 16 and 18.[57] In September, Valeant licensed Brodalumab from the company for up to US$445 million.[58][59] On 6 November, it was reported that AstraZeneca had acquired ZS Pharma for US$2.7 billion.[60] In December, the company announced its intention to acquire the respiratory portfolio of Takeda Pharmaceutical – namely Alvesco and Omnaris – for US$575 million[61] A day later, the company announced it had taken a 55% majority stake in Acerta for US$4 billion; the transaction included commercial rights to Acerta's irreversible oral Bruton's tyrosine kinase inhibitor, acalabrutinib (ACP-196), which under development at that time.[62] In 2015, AstraZenica was the eighth-largest drug company in the world based on sales revenue.[63]

2017

[edit]

In July 2017, the company's CEO Pascal Soriot said that Brexit would not affect its commitment to its current plans in the United Kingdom. However, it had slowed decision making for new investment projects waiting for a post-Brexit regulatory regime to settle down.[64] Two months later, the firm's chairman Leif Johansson planned in taking the "first steps" in moving its research and manufacturing operations away from the United Kingdom, if there is a hard Brexit.[65] Soon after, executive vice president Pam Cheng stated that AstraZeneca had ignited startup of duplicate QA testing facility in Sweden and has initiated hiring in Sweden.[66]

In 2017, it was the eleventh largest drug company in the world based on sales and ranked seventh based on R&D investment.[67]

2018

[edit]

In February 2018, AstraZeneca announced it was spinning off six early-stage experimental drugs into a new biotechnology company, known as Viela Bio, valued at US$250 million.[68]

On 6 December 2018, AstraZeneca purchased nearly 8% of the American pharmaceutical business, Moderna.[69]

2019

[edit]

In March 2019, AstraZeneca announced it will pay up to US$6.9 billion to work with Daiichi Sankyo Co Ltd on an experimental treatment for breast cancer. AstraZeneca plans to use some of the proceeds of a US$3.5 billion share issue to fund the deal. The deal on the drug known as trastuzumab deruxtecan sent shares in Japan's Daiichi soaring 16%.[70]

In September 2019, the company announced that it would cease drug production at its German headquarters in Wedel, leading to the loss of 175 jobs by the end of 2021.[71][72]

In October 2019, AstraZeneca announced it would sell the global commercial rights for its drug to treat acid reflux to German pharmaceutical company Cheplapharm Arzneimittel GmbH for as much as US$276 million.[73][74]

2020

[edit]

In February 2020, AstraZeneca agreed to sublicense its global rights (except Europe, Canada and Israel) to the drug Movantik, to Redhill Biopharma.[75]

In June 2020, AstraZeneca made a preliminary approach to Gilead Sciences about a potential merger, worth almost US$240 billion.[76][77] However, these plans were subsequently dropped because it would have distracted the company from its own pipeline and ongoing COVID-19 vaccine efforts.[78]

In July 2020, the business entered into its second collaboration with Daiichi Sankyo, centred around the development of DS-1062, an antibody drug conjugate. The deal could potentially be worth up to US$6 billion for Daiichi.[79]

In September 2020, AstraZeneca acquired the preclinical oral PCSK9 inhibitor program from Dogma Therapeutics.[80]

On 27 December 2020, AstraZeneca CEO Pascal Soriot said that they have “figured out the winning formula” with their two-dose system with the Oxford University’s COVID-19 vaccine.[81] Three days later, the United Kingdom approved the emergency use of the Oxford–AstraZeneca COVID-19 vaccine.[82][83][84]

2021

[edit]

In July 2021, AstraZeneca acquired Alexion Pharmaceuticals.[85][86] In October 2021, the company, through Alexion, acquired Caelum Biosciences and its monoclonal treatment (CAEL-101) for light chain (AL) amyloidosis for up to $500 million.[87][88]

2022

[edit]

In July 2022, the company announced it would acquire TeneoTwo for up to $1.3 billion, increasing its blood cancer drug offering.[89] In October 2022, it was announced that it would acquire LogicBio Therapeutics, which was active in clinical-stage genomic medicine.[90][91]

In November 2022, it was announced AstraZeneca had acquired the Amsterdam-headquartered clinical-stage biotechnology company, Neogene Therapeutics.[92]

2023

[edit]

In January, AstraZeneca announced it would acquire CinCor Pharma for $1.8 billion.[93]

In November 2023, AstraZeneca launched a new global health tech business, Evinova, that focused on provide global services to CROs and pharma companies to design, run and monitor clinical trials.[94]

In December 2023, AstraZeneca announced that it would acquire an RSV vaccine developer, Icosavax for $1.1 billion.[95] Later that month, AstraZeneca agreed to acquire clinical-stage biopharmaceutical developer of cell therapies for the treatment of cancer and autoimmune diseases, Gracell Biotechnologies, in a deal valued at up to $1.2 billion.[96] Both the acquisitions were completed in February 2024.[97][98]

2024

[edit]

In March 2024, AstraZeneca announced it would acquire Amolyt Pharma in exchange for $1.05 billion.[99] That same month, the firm also announced the acquisition of Fusion Pharmaceuticals Inc for $2 billion in cash.[100]

In July 2024, National Institute for Health and Care Excellence (Nice) blocked the National Health Service (NHS) from providing Enhertu, an innovative treatment for advanced HER2-low breast cancer, due to AstraZeneca and Daiichi Sankyo not offering a low enough price. Nice's decision, the first rejection of a breast cancer treatment in six years, highlighted the financial challenges of funding complex medicines, with Enhertu costing £117,857 per treatment course. Despite approval by the Medicines and Healthcare Regulatory Agency, Nice's non-recommendation meant the drug could only be available privately or under separate funding in Scotland. Clinical trials showed Enhertu extended patients' lives by five months compared to chemotherapy, but Nice and the companies could not agree on a new price.[101]

In February 2024, the chief executive faced criticism from corporate governance experts and AstraZeneca investors regarding his excessive pay.[102]

In December 2024, the company announced the appointment of Rene Haas and Birgit Conix to its board as non-executive directors.[103] Both appointments will be effective from January 2025 and February 2025 respectively.[103]

2025

[edit]

In January 2025, the company announced the withdrawal of plans to expand its vaccine manufacturing site in Liverpool, England.[104] In March 2025, the company told the UK Business and Trade Select Committee that the government failed to make a proposed £75 million grant by August 2025, saying "When the offer emerged in October of support to the tune of £75 million, that didn’t then support the revised business case with the new timelines sufficiently.".[104]

In March 2025, AstraZeneca announced the acquisition of Belgian biotech company EsoBiotec for up to $1 billion to enhance its cancer treatment capabilities through EsoBiotec's in vivo cell therapy platform.[105]

In July 2025, AstraZeneca announced plans to invest $50 billion in the United States by 2030.[106]

Acquisition history

[edit]

The following is an illustration of the company's major mergers and acquisitions and historical predecessors:[107]

  • AstraZeneca
    • AstraZeneca (Merged 1999)
    • KuDOS Pharmaceuticals (Acq 2005)
    • MedImmune Biologics
    • Arrow Therapeutics (Acq 2007)
    • Novexel Corp (Acq 2010)
    • Guangdong BeiKang Pharmaceutical Company (Acq 2011)
    • Ardea Biosciences (Acq 2012)
    • Amylin Pharmaceuticals (Acq 2012 jointly with Bristol-Myers Squibb)
    • Spirogen (Acq 2013)
    • Pearl Therapeutics[109] (Acq 2013)
    • Omthera Pharmaceuticals[110] (Acq 2013)
    • ZS Pharma (Acq 2015)
    • Alexion Pharmaceuticals[85] (Acq 2021)
      • Proliferon Inc (Acq 2000, restructured into Alexion Antibody Technologies Inc)
      • Enobia Pharma Corp (Acq 2011)
      • Synageva BioPharma (Acq 2015)
      • Wilson Therapeutics (Acq 2018)
      • Syntimmune (Acq 2018)
      • Achillion Pharmaceuticals (Acq 2019)
      • Portola Pharmaceuticals (Acq 2020)
      • Caelum Biosciences (Acq 2021)
    • TeneoTwo (Acq 2022)
    • LogicBio Therapeutics (Acq 2022)
    • Neogene Therapeutics (Acq 2022)
    • CinCor Pharma (Acq 2023)
    • Icosavax (Acq 2024)
    • Gracell Biotechnologies (Acq 2024)
    • Amolyt Pharma (Acq 2024)
    • Fusion Pharmaceuticals Inc (Acq 2024)

Operations

[edit]
The AstraZeneca R&D facility in Mölndal near Gothenburg, Sweden
The new AstraZeneca Corporate HQ under construction in Cambridge, United Kingdom

AstraZeneca develops, manufactures and sells pharmaceutical and biotechnology products to treat disorders in the oncology, cardiovascular, gastrointestinal, infection, neuroscience, respiratory and inflammation areas.[111]

AstraZeneca has its corporate headquarters in Cambridge, United Kingdom, and its main research and development (R&D) centres are in Cambridge (UK), Gaithersburg (Maryland, US), Mölndal in Gothenburg (Sweden), and Warsaw (Poland).[112] In 2025 the company opened a new cell therapy manufacturing facility in Rockville, Maryland.[113]

Headquarters

[edit]

AstraZeneca's global headquarters are located in the Cambridge Biomedical Campus adjacent to Addenbrooke's Hospital in Cambridge, England. The facility, known as the Discovery Centre, was designed by Swiss architecture firm Herzog & de Meuron[114] and officially opened by Prince Charles on the 23 November 2021.[115] The building is designed to accommodate over 2,200 scientists across 16 laboratories covering approximately 19,000 square metres (200,000 sq ft). It was built at a cost of approximately £1 billion.[116]

In September 2025, the Discovery Centre was shortlisted for the Stirling Prize.[117]

Cambridge-Gothenburg flights

[edit]

In 2015, AstraZeneca arranged for the establishment of a direct air route between Cambridge and Gothenburg, which began operation on 2 March 2015.[118] The company reserved 20 of the 32 seats on each flight, with the remaining seats available to the public, which was operated SUN-AIR for British Airways.[119] The service connects AstraZeneca’s global headquarters in Cambridge with its research facility in Gothenburg.[120] The service operated four days per week and was intended to support collaboration between staff in the two locations, allowing same-day travel for meetings. The route ended as a scheduled public service in 2016 due to insufficient demand,[121] but these flights continue for AstraZeneca employees as of 2024.[122]

Orphan drugs

[edit]

In April 2015, AstraZeneca's drug tremelimumab was approved as an orphan drug for the treatment of mesothelioma in the United States.[123] In February 2016, AstraZeneca announced that a clinical trial of tremelimumab as a treatment for mesothelioma failed to meet its primary endpoint.[124]

Senior management

[edit]

As of 2008, David Brennan was paid US$1,574,144 for his role as chief executive officer.[125]

On 26 April 2012, it was announced that Brennan was to retire in early June of that year.[126] In August 2012, Pascal Soriot was named CEO of AstraZeneca.[127]

It was also announced that Leif Johansson would succeed Louis Schweitzer as non-executive chairman on 1 June 2012, three months earlier than previously announced, and would become Chairman of the Nomination and Governance Committee after the 2012 Annual General Meeting.[126]

The company's non-executive Board directors are Philip Broadley, Euan Ashley, Michel Demaré, Deborah DiSanzo, Diana Layfield, Sheri McCoy, Tony Mok, Nazneen Rahman, Andreas Rummelt, and Marcus Wallenberg.[128]

Lobbying

[edit]

Political lobbying

[edit]

AstraZeneca is a member of the Personalized Medicine Coalition, a medical research advocacy group that lobbies on behalf of the pharmaceutical industry.[129]

Controversies

[edit]

Seroquel

[edit]

In April 2010, AstraZeneca settled a qui tam lawsuit brought by Stefan P. Kruszewski for US$520 million to settle allegations that the company defrauded Medicare, Medicaid, and other government-funded health care programs in connection with its marketing and promotional practices for the blockbuster atypical antipsychotic, Seroquel. According to the settlement agreement, AstraZeneca targeted its illegal marketing of the anti-psychotic Seroquel towards doctors who do not typically treat schizophrenia or bipolar disorder, such as physicians who treat the elderly, primary care physicians, pediatric and adolescent physicians, and in long-term care facilities and prisons.[130]

In March 2011, AstraZeneca settled a lawsuit in the United States totalling US$68.5 million to be divided up to 38 states.[131]

Nexium

[edit]

The company's most commercially successful medication is esomeprazole (Nexium). The primary uses are treatment of gastroesophageal reflux disease, treatment and maintenance of erosive esophagitis, treatment of duodenal ulcers caused by Helicobacter pylori, prevention of gastric ulcers in those on chronic NSAID therapy, and treatment of gastrointestinal ulcers associated with Crohn's disease. When it is manufactured the result is a mixture of two mirror-imaged molecules, R and S. Two years before the omeprazole patent expired, AstraZeneca patented S-omeprazole in pure form, pointing out that since some people metabolise R-omeprazole slowly, pure S-omeprazole treatment would give higher dose efficiency and less variation between individuals.[132] In March 2001, the company began to market Nexium, as it would a brand new drug.[133]

The (R)-enantiomer of omeprazole is metabolized exclusively by the enzyme CYP2C19, which is expressed in very low amounts by 3% of the population. Treated with a normal dose of the enantiomeric mixture, these persons will experience blood levels five-times higher than those with normal CYP2C19 production. In contrast, esomeprazole is metabolized by both CYP2C19 and CYP3A4, providing less-variable drug exposure.[134] While omeprazole is approved only at doses of up to 20 mg for the treatment of gastroesophageal reflux,[135] esomeprazole is approved for doses up to 40 mg.[136]

In 2007, Marcia Angell, former editor-in-chief of the New England Journal of Medicine and a lecturer in social medicine at the Harvard Medical School, said in Stern, a German-language weekly newsmagazine, that AstraZeneca's scientists had misrepresented their research on the drug's efficiency, saying: "Instead of using presumably comparable doses [of each drug], the company's scientists used Nexium in higher dosages. They compared 20 and 40 mg Nexium with 20 mg Prilosec. With the cards having been marked in that way, Nexium looked like an improvement – which however was only small and shown in only two of the three studies."[137]

Bildman fraud, sexual harassment and faithless servant clawback

[edit]

On 4 February 1998, Astra USA sued Lars Bildman, its former president and chief executive officer, seeking US$15 million for defrauding the company.[138] The sum included US$2.3 million in company funds he allegedly used to fix up three of his homes, plus money the company paid as the result of the EEOC investigation. Astra's lawsuit alleged Bildman sexually harassed and intimidated employees, used company funds for yachts and sex workers, destroyed documents and records, and concocted: "tales of conspiracy involving ex-KGB agents and competitors. This was in a last-ditch effort to distract attention from the real wrongdoer, Bildman himself." Bildman had already pleaded guilty in US District Court for failing to report more than US$1 million in income on his tax returns.[139] In addition, several female co-workers filed personal sexual-harassment lawsuits against Bildman.[140] In April 1998, Bildman was sentenced to 21 months in prison three months after he pled guilty to filing false Federal tax returns.[141][139]

In February 1998, AstraZenaca's U.S. affiliate Astra U.S.A. agreed to a $10 million settlement after an Equal Employment Opportunity Commission investigation which started in May 1996 found that sexual harassment against female employees.[142] 120 former female employees of Astra were interviewed during the inquiry, with about 80 of them being identified as able to file claims.[142] Astra U.S.A. also issued a statement of apology for the hostile work environment.[142]

In Astra USA v. Bildman, 914 N.E.2d 36 (Mass. 2009), applying New York's faithless servant doctrine, the court held that a company's employee who had engaged in financial misdeeds and sexual harassment must "forfeit all of his salary and bonuses for the period of disloyalty".[143] The court held that this was the case even if the employee "otherwise performed valuable services", and that the employee was not entitled to recover restitution for the value of those other services.[143][144] The decision attracted a good deal of attention by legal commentators.[145]

CAFÉ study

[edit]

In 2004, University of Minnesota research participant Dan Markingson took his own life while enrolled in an industry-sponsored pharmaceutical trial comparing three FDA-approved atypical antipsychotics: Seroquel (quetiapine), Zyprexa (olanzapine), and Risperdal (risperidone). University of Minnesota Professor of Bioethics Carl Elliott noted that Markingson was enrolled in the study against the wishes of his mother, Mary Weiss, and that he was forced to choose between enrolling in the study or being involuntarily committed to a state mental institution.[146] A 2005 FDA investigation cleared the university. Nonetheless, controversy around the case has continued. A Mother Jones article[146] resulted in a group of university faculty members sending a public letter to the university Board of Regents urging an external investigation into Markingson's death.[147]

Transfer mispricing

[edit]

In February 2010, AstraZeneca agreed to pay £505 million to settle a UK tax dispute related to transfer mispricing.[148][149]

Conflicting commitments to the UK and the EU over COVID-19 vaccines

[edit]
Seat of the European Commission, which negotiated a contract with AstraZeneca

In August 2020, AstraZeneca made an advance purchase agreement with the European Commission and the EU member states for the supply of COVID-19 vaccines:

"13.1. AstraZeneca represents, warrants and covenants to the Commission and the Participating Member States that: [...] (e) it is not under any obligation, contractual or otherwise, to any Person or third party in respect of the Initial Europe Doses or that conflicts with or is inconsistent in any material respect with the terms of this Agreement or would impede the complete fulfilment of its obligation under this Agreement;"[150]

However, the UK Secretary of State for Health and Social Care, Matt Hancock, declared in March 2021 that the United Kingdom had been given "exclusivity" and that the EU's treaty was "inferior".[151][152] After placing the order for AstraZeneca's vaccine, the European Commission mistakenly assumed that it had enough vaccines and initially ordered only 200 million doses from Pfizer–BioNTech when the manufacturers offered 500 million doses to the EU in November 2020.[153]

However, the contract that AstraZeneca reached with the UK was very similar to that it reached with the EU, and it also contained the phrase "best reasonable efforts"; the UK contract was signed on 28 August 2020, a day after the contract with the EU.[154] The key difference seems to be that AstraZeneca entered into a preliminary agreement with the U.K. back in May 2020 which arranged for "the development of a dedicated supply chain for the U.K."[155] The failure to produce the vaccine in the anticipated quantities contributed to the low vaccination rates of vulnerable populations of the European Union at the beginning of the outbreak of more virulent variants of SARS-CoV-2 in early 2021.[156]

Operations in China and investigation

[edit]

AstraZeneca's reputation in China was tarnished when its Chinese subsidiary did not quickly donate to relief efforts after the 2008 Sichuan earthquake.[157]: 121  Typically, donations for disaster relief in China are made through funds established through the Chinese Ministry of Civil Affairs and its subordinate organization, the Red Cross Society of China.[157]: 121  AstraZeneca had a corporate rule prohibiting foreign subsidiaries from making donations to local governments, and the company construed this rule as prohibiting donations for Sichuan earthquake relief efforts.[157]: 121  AstraZeneca's Chinese subsidiary suffered a major backlash for its failure to donate.[157]: 121  Corporate approval was eventually given for the Chinese subsidiary to donate, but only after a long delay.[157]: 121 

During the early 2020s, AstraZeneca expanded its R&D pipeline within China, increasing its investment in the country; the firm also signed licensing agreements with nine separate biotech firms in China that have been collectively valued at $6.5 billion.[158][159]

In May 2023, AstraZeneca's China president, Leon Wang, stated that the company aims to be a "patriotic" company in China that "loves the Communist Party."[160] On 30 October 2024, AstraZeneca revealed that Wang was under investigation by Chinese authorities and had been detained.[161] The China business is now being run by Michael Lai, the general manager.[162]

In November 2024, it was announced that Chinese officials had widened their investigation under a national anti-corruption campaign targeting healthcare. Among the allegations, former AstraZeneca employees are accused of falsifying genetic tests to secure reimbursement for the company’s lung cancer drug, Tagrisso.[163] Several current and former company executives are also being investigated for potentially breaching data privacy laws and for the suspected illegal importation of certain cancer drugs – likely including Enhertu, Imfinzi and Imjudo – from Hong Kong.[164]

Operations in Russia

[edit]

Following Russia's invasion of Ukraine in 2022, AstraZeneca faced criticism for maintaining its operations and continuing certain clinical trials in Russia, despite promising to halt new investments in the country.[165] While several international pharmaceutical companies announced suspensions of new clinical studies in Russia after the conflict began, AstraZeneca moved forward with a study for a new COVID-19 prevention drug, essential for its registration in Russia.[166]

See also

[edit]

References

[edit]
[edit]
Revisions and contributorsEdit on WikipediaRead on Wikipedia

AstraZeneca

View on Grokipedia
from Grokipedia
AstraZeneca plc is a global, science-led company headquartered in , , specializing in the discovery, development, and commercialization of prescription medicines. Formed in 1999 through the merger of the Swedish and the British Zeneca Group PLC, it combines strengths in and to address major areas of unmet medical need. The company prioritizes three main therapy areas: , rare diseases, and BioPharmaceuticals, encompassing respiratory and immunology, cardiovascular, renal, and metabolic diseases. Key products include treatments such as Tagrisso () for non-small cell and Imfinzi () for various cancers, which have driven significant revenue growth through targeted therapies extending patient survival. AstraZeneca maintains a robust pipeline with over 190 projects, including late-stage candidates aimed at transformative outcomes in precision medicine. AstraZeneca gained prominence during the with its , co-developed with the and marketed as Vaxzevria, which demonstrated efficacy of around 70-80% against symptomatic infection in clinical trials, with higher protection against hospitalization and death. However, post-authorization data revealed rare instances of with (TTS), occurring at rates of approximately 1-2 per 100,000 doses, prompting regulatory pauses and label updates; risk-benefit analyses consistently showed net benefits in high-transmission settings, particularly for preventing severe outcomes. These events underscored challenges in vaccine , where early signals from limited data influenced public perception amid evolving epidemiological contexts.

History

Origins and Pre-Merger Development

Astra AB was founded on December 10, 1913, in , , through the initiative of more than 400 doctors and apothecaries who pooled resources to create a company and became its initial shareholders. The company initially focused on producing amid Sweden's limited domestic pharmaceutical infrastructure, launching its first products in 1914: Digitotal, a digitalis-based heart medication, and Glukofos, a nutritional supplement derived from glucose and phosphates. By the , Astra had expanded production capabilities and begun emphasizing (R&D), shifting from basic to innovative drug synthesis. Key early advancements included the 1943 introduction of Xylocaine (lidocaine), a local anesthetic that became one of the world's best-selling in its class and accounted for 24% of Astra's sales (SKr 696 million) by 1984. In 1948, Astra commercialized penicillin and further anesthetic formulations, bolstering its reputation in anti-infectives and . The company divested non-core operations in the to concentrate exclusively on pharmaceuticals, establishing global subsidiaries—reaching 40 by the mid-1990s—and investing heavily in R&D for cardiovascular, gastrointestinal, and respiratory therapies. Blockbuster products emerged in the 1980s and 1990s, including Seloken (metoprolol, a beta-blocker for and heart disease) and Losec (omeprazole), a for ulcers that generated US$3.5 billion in annual by 1996, making it the world's top-selling at the time. Financial growth accelerated, with pre-tax earnings surpassing SKr 1 billion in 1985, revenues hitting SKr 6.2 billion in 1988 (with SKr 1.5 billion in pre-tax earnings), and sales climbing to SKr 39 billion by 1996 alongside SKr 13 billion in pre-tax earnings. Under CEO Håkan Mogren from 1988, Astra pursued strategic partnerships, such as a with Merck dissolved in 1998, to enhance U.S. while navigating protections and international expansion. Zeneca Group PLC traced its roots to the pharmaceutical and agrochemical divisions of (ICI), a British conglomerate established in 1926 through the merger of four major chemical firms. ICI's pharmaceuticals arm, dating back to the 1930s, developed early specialties in and respiratory drugs, but faced competitive pressures in the diversified conglomerate structure. In 1993, ICI demerged its life sciences businesses—including pharmaceuticals, agrochemicals, and specialties—to form the independent Zeneca Group PLC, enabling focused investment in high-growth areas; the new entity reported initial sales of £4.44 billion and profits of £647 million. Zeneca prioritized as its largest therapeutic segment, launching key products like Zoladex ( for prostate and ), Casodex ( for ), and Arimidex ( for ), alongside Accolate () for . By 1995, Zeneca's sales had grown to £4.8 billion with operating profits of £894 million, reflecting expansion into over 25 countries and strategic moves like acquiring a 50% stake in U.S.-based Salick Health Care, Inc., to integrate services. The company invested in R&D alliances and efficiencies to counter expirations and generic competition, positioning itself as a leader in targeted therapies while maintaining operations for diversified revenue. Pre-merger, both Astra and Zeneca grappled with industry consolidation, R&D costs exceeding $1 billion annually each, and the need for scale to sustain innovation pipelines, setting the stage for their 1999 union to create a top-tier global player with combined sales approaching $15 billion.

Formation Through Merger (1999)

, a Swedish pharmaceutical firm founded in , and Zeneca Group PLC, a British company demerged from in 1993 with operations in pharmaceuticals and agrochemicals, announced their intent to merge on December 9, 1998, through a formal merger agreement. The transaction, valued at approximately $67 billion, was structured as a "merger of equals" to combine complementary strengths in , global marketing, and product pipelines, aiming to form a leading player in the pharmaceutical and agrochemical sectors. Zeneca initiated the process with a public bid for all outstanding shares of Astra on January 20, 1999, subject to shareholder and regulatory approvals. Regulatory scrutiny focused on potential overlaps in pharmaceuticals, leading to clearances with conditions: the approved the merger on February 18, 1999, while the U.S. consented on March 25, 1999, requiring divestitures of certain overlapping products to preserve competition. Shareholder approvals followed, with the merger completing on , 1999, creating AstraZeneca PLC. In the new entity, former Astra shareholders received 46.5% ownership, while Zeneca shareholders held 53.5%, reflecting the relative sizes and contributions of the two firms. Headquartered in , AstraZeneca integrated operations across , the , and global sites, leveraging Astra's established European pharmaceutical presence and Zeneca's expertise—though the latter division was later divested—to achieve immediate scale as the world's third-largest pharmaceutical company by sales. The merger enabled pooled R&D resources, with combined annual revenues exceeding $13 billion and a of around 65,000 employees, setting the for enhanced in therapeutic areas like gastrointestinal, cardiovascular, and drugs.

Early 2000s Expansion and Challenges

In the years immediately following its 1999 formation, AstraZeneca pursued expansion through key product launches and incremental acquisitions to build its portfolio in gastrointestinal, cardiovascular, and respiratory therapies. , a for acid-related conditions, was introduced in in August 2000 and in the United States in 2001, rapidly becoming a major revenue driver as a successor to Prilosec amid patent transition strategies. , a for management, received FDA approval and launched in 2003, contributing to growth in the market. These efforts supported consistent revenue increases, with annual sales rising from approximately $18.8 billion in 2003 to $26.5 billion in 2006, reflecting an average compound growth rate of around 12% driven by established franchises like Seroquel (quetiapine) for and . Acquisitions complemented organic growth by enhancing R&D capabilities in and biologics. In 2005, AstraZeneca acquired UK-based KuDOS Pharmaceuticals for £120 million to access DNA repair-targeted cancer therapies. This was followed in 2006 by the purchase of Cambridge Antibody Technology for approximately £702 million (about $1.3 billion), securing expertise in antibody engineering and bolstering biologics development. Such moves aligned with increased R&D , which reached $3.86 per share in earnings contribution by 2006, amid efforts to diversify beyond small-molecule drugs. However, expansion faced significant challenges from regulatory and legal scrutiny over practices. In June 2005, the fined AstraZeneca €60 million (about $79 million at the time) for abusing its dominant market position by misusing the system to delay generic for Losec (omeprazole), its blockbuster acid-suppression ; the infringement spanned 1993 to 2000 and involved misleading national patent offices on product formulations and falsely representing regulatory to extend exclusivity. This decision highlighted tensions between innovation incentives and , with the Commission arguing such tactics discouraged R&D by artificially prolonging monopolies. Concurrently, AstraZeneca navigated multiple litigations, including challenges to its metoprolol succinate formulations for , where courts later invalidated claims on double-patenting grounds, and Canadian proceedings under Notice of Compliance regulations to enforce compliance for innovator drugs. These issues underscored vulnerabilities in -dependent models as generics pressured margins on maturing products like Losec.

Patent Cliff Navigation (2007-2012)

During 2007–2012, AstraZeneca confronted a severe cliff, with analysts projecting up to 38% of its at risk from expirations on major blockbusters over the subsequent five years. Key losses included Arimidex (), a treatment with U.S. exceeding $900 million annually, whose compound expired on December 27, 2009, extended by pediatric exclusivity to June 27, 2010. Seroquel (), an generating over $5 billion in peak global , faced U.S. expiry in September 2011, with pediatric exclusivity ending March 26, 2012, triggering rapid generic entry and sharp erosion. These events contributed to a 16% quarterly drop to $7.28 billion by late 2012, exacerbating pressures from earlier expiries like Zoladex formulations. To mitigate the cliff, AstraZeneca pursued defensive patent litigation, securing U.S. court rulings that upheld formulation patents for Seroquel XR (extended-release ), delaying generic competition until November 2017. The company also implemented aggressive cost controls, announcing in February 2012 the elimination of 7,300 positions—over 2,000 in R&D—as part of a broader to streamline operations and redirect resources toward high-potential pipelines in and respiratory diseases. This included a strategic pivot to biologics, bolstered by the $15.2 billion acquisition of MedImmune in , which enhanced capabilities in therapeutics amid declining small-molecule revenues. Despite these measures, the period saw net profit plummet 37% to $6.3 billion in , reflecting the structural challenge of replacing lost exclusivity with nascent products like Brilinta (ticagrelor), approved in 2011 but slow to gain . AstraZeneca's annual reports emphasized focus, yet critics noted over-reliance on litigation and cuts risked long-term pipeline vitality, as R&D spending contracted amid the revenue squeeze. By 's end, the firm warned of ongoing headwinds, underscoring the patent cliff's causal role in shifting priorities toward efficiency over expansion.

Restructuring and Key Acquisitions (2013-2020)

In March 2013, AstraZeneca announced a major program to cut costs amid revenue pressures from patent expirations on blockbuster drugs like Seroquel and Arimidex, including the elimination of 1,600 positions and consolidation of R&D activities into three primary hubs: Cambridge, United Kingdom; , United States; and Mölndal, . This followed an earlier plan for 2,300 reductions in sales, general, and administrative roles, resulting in a $2.3 billion one-time charge aimed at annual savings of approximately $1.5 billion by 2016. The initiatives closed underutilized sites and shifted focus toward high-potential therapeutic areas like and respiratory diseases. As part of this operational overhaul, AstraZeneca selected the for its new global R&D center and corporate headquarters in June 2013, with up to 400 staff relocating by late 2013 ahead of the facility's completion, fully operational by 2016 to foster collaboration in a biotech cluster. Further job reductions followed, including 550 global positions in February 2014, increasing the restructuring program's total cost to $2.5 billion, and 700 U.S. roles in December 2016, primarily affecting and administrative staff. A pivotal external challenge occurred in 2014 when launched an unsolicited takeover bid, escalating to a final proposal valuing AstraZeneca at £69 billion ($119 billion), which the board rejected in May, arguing it undervalued the company's long-term prospects and pipeline under CEO Pascal Soriot's strategy. abandoned the effort in late May after failing to secure agreement, allowing AstraZeneca to maintain independence and pursue internal growth. To rebuild its pipeline, AstraZeneca executed targeted acquisitions, including the October 2013 purchase of Spirogen, a UK-based biotech developing antibody-drug conjugates for cancer, for up to $440 million. In 2015, the company spun off its antibiotics business into a standalone entity after failing to find a buyer, focusing resources on core innovative medicines. Later deals emphasized , such as partnerships and buys enhancing targeted therapies, though divestitures like the 2016 commercialization rights transfer of anesthetics portfolio to for up to $770 million supported non-core asset optimization. These moves, combined with cost discipline, positioned AstraZeneca for revenue stabilization by late decade.

COVID-19 Response and Post-Pandemic Growth (2021-2025)

In early 2021, AstraZeneca accelerated the global rollout of its , Vaxzevria (also known as AZD1222 or Covishield in some regions), developed in collaboration with the using a chimpanzee adenovirus vector platform. The vaccine received emergency authorization in the United Kingdom on December 30, 2020, followed by conditional marketing authorization from the on January 29, 2021, enabling widespread deployment amid supply disputes with the over delivery shortfalls. Phase III trials reported efficacy rates of approximately 76% against symptomatic , with interim data suggesting up to 90% protection when a half-dose was administered first, though subsequent analyses adjusted these figures downward following data monitoring board recommendations for transparency. Safety concerns emerged in March 2021, prompting temporary suspensions in several European countries after reports of rare thrombosis with thrombocytopenia syndrome (TTS), characterized by unusual blood clots and low platelet counts. The EMA's Committee concluded a possible causal link to TTS, estimating an incidence of about 1 in 100,000 doses, predominantly in younger adults, while affirming that benefits outweighed risks given COVID-19's higher thrombotic complications. AstraZeneca later acknowledged in a 2024 UK court document that the could, in very rare cases, cause TTS, amid ongoing litigation from affected individuals. Despite these issues, Vaxzevria was distributed at cost price to low- and middle-income countries via , administering over 3 billion doses globally by mid-2023, particularly in regions where mRNA alternatives were less accessible. The contributed significantly to AstraZeneca's revenue, which rose 41% to $37.4 billion, including vaccine-related income, though core pharmaceutical sales grew 26% excluding it. By , increased 18% to $44.4 billion, but demand waned as variants reduced efficacy against infection (though boosters maintained protection against severe disease) and booster programs shifted toward mRNA options in high-income markets. Sales ceased after 2023, with AstraZeneca withdrawing European marketing authorization in March 2024 and global authorizations by May 2024 due to surplus supply and low uptake. Post-pandemic, AstraZeneca refocused on its , , and portfolios, driving revenue growth independent of COVID products. In 2023, total revenue reached $45.8 billion (up 3%), with oncology contributing over $17 billion from drugs like Tagrisso and Enhertu; excluding COVID, growth was 15%. The company achieved 2024 revenue of $54.1 billion (up 21%), fueled by nine regulatory approvals and expansions in antibody-drug conjugates and therapies, with core rising 19%. Through the first half of 2025, revenue grew 11% to $28 billion, led by double-digit increases in (up 20%) and biopharmaceuticals, positioning AstraZeneca to target $80 billion annual revenue by 2030 via pipeline advancements in precision medicine.

Mergers, Acquisitions, and Divestitures

Major Acquisitions

In 2007, AstraZeneca acquired MedImmune, Inc., a U.S.-based company specializing in biologics and vaccines, for $15.2 billion in cash. This deal provided AstraZeneca with a mature biologics platform, including manufacturing capabilities and a pipeline of monoclonal antibodies, marking its entry into the biologics market at a time when small-molecule patents were facing expiration pressures. AstraZeneca continued its acquisition strategy in the to address gaps in specific therapeutic areas. In 2012, it purchased Ardea Biosciences for $1.26 billion, gaining lesinurad, a urate transporter inhibitor for treatment that complemented AstraZeneca's existing metabolic portfolio. In December 2013, AstraZeneca acquired Bristol-Myers Squibb's global alliance assets, including rights to drugs like Onglyza (saxagliptin) and Kombiglyze (saxagliptin/metformin), for an initial payment of $2.7 billion plus contingent milestone payments totaling up to $1.4 billion. In November 2015, the company bought ZS Pharma for $2.7 billion, adding zilebesiran, an therapeutic for , to bolster its cardiovascular and renal offerings. In February 2016, AstraZeneca secured a 55% stake in Acerta Pharma for an upfront $2.5 billion, with an option to acquire the remainder; this later expanded to full ownership, bringing , a BTK inhibitor for hematologic malignancies, into its lineup. The most transformative acquisition occurred in December 2020, when AstraZeneca agreed to buy for $39 billion in a mix of cash and shares, completed on July 21, 2021. Alexion's focus on s added blockbuster drugs like Soliris () and Ultomiris (), complement inhibitors generating over $3 billion in annual sales, and expanded AstraZeneca's presence in while diversifying revenue beyond . This deal, AstraZeneca's largest to date, was financed partly through $13.3 billion in cash and new shares, aiming to leverage Alexion's high-margin model amid maturing core franchises. In 2024, AstraZeneca accelerated acquisitions in and cell therapies. It acquired Fusion Pharmaceuticals in March for $2.4 billion, gaining actinium-based radioconjugates like FPI-2265 for to advance targeted radioligand therapies. The company also completed deals for Gracell Biotechnologies in February (undisclosed value, focused on CAR-T therapies like GC012F for autoimmune diseases), Icosavax in February (up to $1.1 billion for protein nanoparticle vaccines), and Amolyt Pharma in March (undisclosed, adding analogs for rare endocrine disorders). In March 2025, AstraZeneca agreed to acquire EsoBiotec for up to $1 billion, including $425 million upfront, to develop cell therapies using engineered E. coli for solid tumor treatment. These moves reflect a strategic emphasis on next-generation modalities amid competitive pressures in traditional small molecules.

Strategic Divestitures and Restructuring

In response to patent expirations and to prioritize investments in , rare diseases, and other high-potential areas, AstraZeneca executed multiple divestitures of mature or non-core assets starting in the mid-2010s. These transactions generated cash inflows exceeding $3 billion cumulatively by 2021, enabling funding for acquisitions like and bolstering R&D spending, which reached $10.5 billion in 2024. The strategy reflected a shift away from commoditized generics and low-margin portfolios toward innovative biologics and specialty medicines, amid competitive pressures in segments. Key divestitures included the 2016 sale of ex-US rights to drugs Onglyza and Kombiglyze XR to for up to €1 billion ($1.1 billion), allowing AstraZeneca to exit certain cardiovascular and metabolic assets outside its core focus. In 2018, the company divested U.S. rights to four non-core branded drugs—Atacand, Atacand HCT (for ), Arimidex (for ), and Casodex (for )—to ANI Pharmaceuticals for $46.5 million upfront plus royalties and milestones, streamlining its U.S. commercial operations. Further sales encompassed the 2019 transfer of its small-molecule anti-infectives portfolio to for $110 million upfront and up to $490 million in milestones, exiting a declining antibiotics market. By 2021, AstraZeneca offloaded global rights to treatments Seroquel and Seroquel XR to Cheplapharm Arzneimittel for €350 million ($410 million) plus royalties, and inflammatory bowel disease drugs Entocort and Uceris to for $300 million, divesting and holdings deemed outside strategic priorities. Complementing these asset sales, AstraZeneca implemented successive restructuring programs to enhance and reduce costs. In 2012, it launched initiatives to reorganize R&D, commercial operations, and , targeting gains through site consolidations and workforce reductions of about 4,000 roles globally by 2016. A major 2016 effort aimed at $1.5 billion in annual savings by 2020 involved reshaping the network, including closures of facilities in , , and , alongside investments to counter the Crestor expiry. More recently, in 2024, the company initiated a multi-year program projecting $1.1 billion in recurring savings by end-2026, encompassing approximately 700 U.S. position eliminations and broader efficiency measures across and administrative functions, driven by post-pandemic cost pressures and integration of acquired entities like Alexion. These actions, while incurring one-time charges (e.g., $1.4 billion in 2012-related costs), supported margin expansion, with core operating margins rising to 37% in 2024.

Business Operations

Global Headquarters and Organizational Structure

AstraZeneca PLC maintains its global headquarters at 1 Francis Crick Avenue, , , CB2 0AA, . This site serves as the central hub for corporate functions, integrating with executive leadership following a $1.3 billion investment in constructing the facility as both a global R&D center and corporate headquarters. The relocation from to , initiated around 2015, aimed to foster proximity to scientific talent and innovation ecosystems in the . The company's organizational structure is governed by a , chaired by Michel Demaré since April 2023, which oversees strategy, , and through specialized committees including , , nomination, and . Day-to-day operations are directed by the Senior Executive Team (SET), led by Chief Executive Officer , who has held the position since October 2012. The SET includes executive vice presidents responsible for key functions such as Oncology Business Unit, BioPharmaceuticals Business Unit, International operations, R&D in specific therapeutic areas, and global operations including IT and sustainability. AstraZeneca organizes its business primarily around three core BioPharmaceuticals areas: , BioPharmaceuticals (encompassing Cardiovascular, Renal and ; and Respiratory & ), and (integrated via the Alexion acquisition). This structure is complemented by regional operations, notably and International markets, with over 89,900 employees worldwide supporting these divisions. As a dual-listed on the London Stock Exchange (AZN), (AZN), and also traded on the Stockholm Stock Exchange (AZN), governance emphasizes accountability to shareholders while aligning with ethical and sustainable practices.

Manufacturing Facilities and Supply Chain

AstraZeneca operates a global network of 28 manufacturing sites across 16 countries, focusing on the production of small molecules, biologics, vaccines, and specialty therapies such as antibody-drug conjugates (ADCs). These facilities support the company's pipeline in oncology, cardiovascular, respiratory, and rare diseases, with an emphasis on scaling production for high-demand products like Enhertu and its COVID-19 vaccine during peak periods. In the United States, AstraZeneca maintains multiple manufacturing hubs, including expansions in , for continuous manufacturing processes and , for specialty formulations. A notable recent development is the $4.5 billion investment announced in October 2025 for a new active pharmaceutical ingredient (API) facility in —described as the company's largest-ever manufacturing site—which will produce drug substances for and other therapies, creating approximately 600 direct jobs and 3,000 construction roles. This is part of a broader $50 billion commitment to U.S. manufacturing and R&D through 2030, aimed at enhancing domestic production capacity amid geopolitical supply risks. Internationally, facilities include a new $1.5 billion ADC manufacturing plant in , where groundbreaking occurred in 2024 and operations are set to employ over 800 workers for cancer medicines production. In , a site under construction near , , in , will add 100 jobs and commence operations by early 2026. Mexico's Lomas Verdes site handles manufacturing, packaging, and quality control for regional supply. Advanced digitalized sites in and have been recognized by the World Economic Forum's Global Lighthouse Network for innovative manufacturing practices integrating AI and . AstraZeneca's supply chain employs a dual strategy emphasizing resilience through localized production, diversified sourcing, and digital optimization to mitigate disruptions from raw material shortages or geopolitical events. The company sources raw materials via complex chains involving miners, processors, and intermediaries, with sustainability targets requiring supplier engagement to reduce scope 3 emissions and ensure data quality for compliance. Challenges include potential product shortages from supply difficulties, as noted in the company's 2023 risk disclosures, which could impact sales and reputation; during the COVID-19 pandemic, AstraZeneca optimized processes for vaccine yield and quality to address scale-up demands. Recent initiatives leverage industrial-scale digital tools for efficiency, such as renewable natural gas integration at U.S. sites, while fostering agility through supplier reassessments and innovation in planning.

Recent Investments and Expansion Initiatives

In January 2026, AstraZeneca announced plans to invest $15 billion in China through 2030 to expand medicines manufacturing and research and development. The investment will enable the company to achieve end-to-end cell therapy capabilities in China as the first global biopharmaceutical firm to do so, develop treatments for cancer, blood disorders, and autoimmune diseases, and expand manufacturing sites in Wuxi, Taizhou, Qingdao, and Beijing, which supply medicines to China and 70 markets worldwide. It will also increase AstraZeneca's workforce in China to more than 20,000 employees. In July 2025, AstraZeneca announced plans to invest $50 billion in the United States by 2030, primarily in manufacturing and research and development infrastructure, amid discussions of potential pharmaceutical tariffs. This commitment builds on prior U.S. expansions and includes a new multi-billion-dollar active pharmaceutical ingredients (API) manufacturing facility in Virginia as its cornerstone, alongside upgrades in Maryland, Texas, and Massachusetts. In October 2025, the company escalated its investment to $4.5 billion, an increase of $500 million from initial plans, targeting the Rivanna Futures site in Albemarle County to produce APIs for and other therapies while creating 3,600 direct jobs. The facility will incorporate advanced and AI to enhance efficiency and . Concurrently, AstraZeneca allocated $445 million to expand its site, adding a 9,000-square-foot building, two new manufacturing lines, and upgraded utilities to double global production of Lokelma, a potassium binder for patients. These U.S.-centric initiatives follow a November 2024 pledge of $3.5 billion in capital expenditures for American R&D and manufacturing expansions, set for completion by 2026, reflecting a strategic pivot toward domestic production to mitigate geopolitical risks. In contrast, AstraZeneca paused a £200 million ($271 million) upgrade to its , research campus in September 2025, citing regulatory and policy uncertainties in Britain.

Research and Development

R&D Investment and Strategic Focus

AstraZeneca allocated $13.583 billion to research and development in 2024, reflecting a 24.22% increase from 2023 and underscoring its commitment to expanding innovative capabilities amid rising operational demands. This expenditure, which trailed only Roche, Merck & Co., and Pfizer among major pharmaceutical firms, supported advancements in core therapeutic modalities and technologies, including antibody-drug conjugates and radioconjugates, as outlined in the company's 2024 annual report. By mid-2025, trailing twelve-month R&D spending had climbed to $14.499 billion, a 26.65% year-over-year rise driven by pipeline intensification. Strategically, AstraZeneca concentrates R&D efforts on oncology, biopharmaceuticals (encompassing cardiovascular, renal, and ; respiratory and ), and rare diseases, prioritizing precision medicine and novel delivery mechanisms to address unmet clinical needs. This patient-centric, science-led approach operates through five global strategic centers in the , , , and , supplemented by activities in over 50 countries, enabling integrated discovery, clinical development, and regulatory navigation. The framework emphasizes causal mechanisms of progression, leveraging empirical from biomarker-driven trials to deprioritize less viable candidates early, thereby optimizing resource allocation toward high-potential assets. Major investments reinforce this focus, including a $50 billion commitment to U.S. and R&D by 2030 to bolster domestic . In , U.S. operations alone invested $4.6 billion in R&D, complemented by a $3.5 billion expansion of and production facilities. Internationally, a $2.5 billion outlay in March 2025 established a new global R&D center in , targeting biotech collaborations and localized to accelerate pipeline progression. These initiatives align with long-term revenue goals exceeding $80 billion by 2030, predicated on sustained R&D productivity rather than incremental refinements.

Pipeline Development and Key Programs

AstraZeneca maintains a robust pipeline focused on advancing novel therapies through innovative modalities, including bispecific antibodies, antibody-drug conjugates, and combination regimens, to target disease mechanisms at multiple levels. As of July 29, 2025, the pipeline encompasses 196 projects, including 19 new molecular entities in late-stage (Phase II/III) development and one under regulatory review, with emphasis on high-unmet-need areas such as precision and chronic inflammatory conditions. The company integrates AI-driven discovery platforms and transparent development processes via its Discovery Centre to accelerate candidate selection and clinical progression, aiming for first- or best-in-class outcomes. Key late-stage programs span core therapy areas, with several poised for Phase III readouts or label expansions in 2025-2026. In , volrustomig—a PD-1/CTLA-4 bispecific —is advancing in Phase II/III trials for non-small cell lung cancer (NSCLC), advanced renal cell carcinoma, and , supported by the eVOLVE-01 study evaluating its efficacy in immune checkpoint combinations. Surovatamig (AZD0486), a CD19xCD28 bispecific T-cell engager, targets B-cell in Phase II, leveraging enhanced T-cell activation for hematologic malignancies. Camizestrant, an oral , progresses in Phase II for estrogen receptor-positive , demonstrating potential potency advantages over prior degraders in biomarker-selected populations.
Therapy AreaKey ProgramPhasePrimary Indication(s)Notable Details
Cardiovascular, Renal & (CVRM)Balcinrenone + DapagliflozinIII with Combination targeting cardiorenal protection mechanisms.
CVRMBaxdrostat + DapagliflozinIII, Aldosterone synthase inhibition paired with SGLT2 for blood pressure and renal outcomes.
CVRMLaroprovstat (AZD0780)IIIDyslipidaemiaOral therapy in AZURE trial assessing lipid-lowering efficacy.
Respiratory & Breztri/TrixeoIII (LCM) (KALOS/LOGOS trials), COPD (ATHLOS/THARROS)Triple inhaled therapy expansions for broader respiratory control.
Respiratory & FasenraIII (LCM) (MANDARA), COPD (RESOLUTE)Anti-IL-5 biologic for eosinophil-driven inflammation.
Respiratory & SaphneloIII (LCM)Systemic (TULIP-SC), (IRIS)Type I inhibitor for modulation.
Rare DiseaseUltomirisIII (LCM)Generalized , (CHAMPION-NMOSD)Long-acting C5 complement inhibitor for neuroinflammatory conditions.
Rare DiseaseKoselugoIII (LCM) type 1 (adult; KOMET trial) extension to adult plexiform neurofibromas.
These programs reflect AstraZeneca's strategy of pursuing label expansions and combinations to extend approved assets while introducing novel entities, with anticipated Phase III data for up to seven new medicines in 2025 to drive momentum.

Partnerships and External Collaborations

AstraZeneca actively pursues external collaborations to augment its capabilities, partnering with firms, academic institutions, and technology companies to integrate innovative modalities such as AI, gene editing, and precision diagnostics into its pipeline. These alliances facilitate risk-sharing in high-cost , access to proprietary platforms, and accelerated development timelines across therapeutic areas including and infectious diseases. At its Gothenburg R&D center in Sweden, AstraZeneca operates the BioVentureHub, an open innovation ecosystem that supports startups and emerging companies in pharmaceuticals, biotechnology, and digital health solutions by providing access to scientific expertise, world-class infrastructure, and collaborative networks to accelerate innovation and bridge development challenges. In , a cornerstone of AstraZeneca's R&D strategy involves longstanding agreements like the 2019 global collaboration with for Enhertu (), an antibody-drug conjugate targeting HER2-positive cancers, which has expanded to additional candidates and generated combined global sales exceeding $2.6 billion in 2023. More recently, in April 2025, AstraZeneca expanded strategic agreements with Tempus to develop a multimodal AI leveraging vast clinical and genomic datasets for insights, aiming to enhance patient stratification and trial efficiency. In September 2025, the company broadened its partnership with to improve early detection of and cancers through advanced genomic analytics. For precision medicine and diagnostics, AstraZeneca announced a partnership with Danaher on May 29, 2025, focused on co-developing AI-powered companion diagnostics to support targeted therapies, including next-generation sequencing tools for identification. In cell and , a November 2023 collaboration with Cellectis provides access to proprietary gene-editing technologies and manufacturing processes for off-the-shelf CAR-T candidates, with potential milestone payments up to $1.2 billion. Emerging infectious disease efforts include a March 2025 agreement with the (CEPI) to advance VHH-based multi-specific antibodies against , targeting prevention during outbreaks through rapid deployment platforms. Additionally, in June 2025, AstraZeneca initiated a $3.3 billion strategic research collaboration with CSPC Pharmaceutical Group, employing AI to expedite oral discovery in undisclosed areas, underscoring a shift toward computational acceleration of early-stage R&D. These partnerships reflect AstraZeneca's emphasis on external innovation to complement internal capabilities, with over 125 active alliances reported as of 2024.

Therapeutic Areas and Products

Oncology Portfolio

AstraZeneca's portfolio encompasses a range of targeted therapies, immunotherapies, antibody-drug conjugates (ADCs), and aimed at treating various solid tumors and hematologic malignancies, with a focus on precision medicine approaches such as EGFR inhibition, blockade, and DNA damage response exploitation. In 2024, generated $22.353 billion in , representing 41% of the company's total and increasing 21% year-over-year at constant exchange rates, driven by established blockbusters and new launches. The portfolio's growth continued into 2025, with sales rising 18% in the second quarter to contribute significantly to overall expansion. Key approved medicines include Tagrisso (osimertinib), a third-generation EGFR tyrosine kinase inhibitor approved for non-small cell lung cancer (NSCLC) harboring EGFR mutations, which generated $3.489 billion in sales in the first half of 2025, underscoring its status as a cornerstone product. Imfinzi (durvalumab), a PD-L1 inhibitor, is indicated for unresectable stage III NSCLC and locally advanced or metastatic urothelial carcinoma, with first-quarter 2024 sales of $1.26 billion reflecting strong uptake in immuno-oncology settings. Lynparza (olaparib), a PARP inhibitor developed in collaboration with Merck & Co., targets BRCA-mutated ovarian, breast, prostate, and pancreatic cancers, bolstering the portfolio's genetic-targeted offerings. ADCs like Enhertu (trastuzumab deruxtecan), partnered with Daiichi Sankyo, address HER2-positive breast and gastric cancers, while Datroway (datopotamab deruxtecan) targets TROP2-expressing solid tumors and received FDA approval in early 2025 for certain indications. Other notable agents include Calquence (acalabrutinib) for B-cell malignancies, Truqap (capivasertib) for PI3K/AKT pathway-driven breast cancer, and Imjudo (tremelimumab) for combination immuno-oncology regimens in NSCLC and hepatocellular carcinoma. The pipeline, updated as of July 29, 2025, features over 50 projects across phases I-III, emphasizing multimodal therapies including bispecific antibodies, next-generation ADCs, and combinations to address resistance and early-stage disease. Late-stage candidates include camizestrant, a next-generation in phase III for estrogen receptor-positive ; volrustomig, a PD-1/CTLA-4 bispecific in phase III for solid tumors such as NSCLC and ; and Datroway expansions into and cancers. Additional efforts target with FPI-2265 (phase II) and glioblastoma with AZD1390 (phase I), alongside lifecycle management for existing drugs like Imfinzi combinations. This breadth supports AstraZeneca's strategy of redefining cancer care through tumor-type agnostic approaches and integration of AI-driven insights for patient selection.

Cardiovascular, Renal, and Metabolism (CVRM)

AstraZeneca's Cardiovascular, Renal, and Metabolism (CVRM) division targets interconnected chronic conditions including cardiovascular disease, chronic kidney disease (CKD), type 2 diabetes (T2D), heart failure (HF), hypertension, and obesity, emphasizing therapies that protect organs, slow disease progression, and address underlying mechanisms like inflammation and fibrosis. The portfolio leverages sodium-glucose cotransporter 2 (SGLT2) inhibitors and other modalities to reduce cardiovascular events, hospitalization risks, and renal decline across indications. In fiscal year 2024, CVRM generated $12,517 million in total revenue, representing 23% of AstraZeneca's overall revenue and marking an 18% year-over-year increase at actual exchange rates (20% at constant exchange rates). Farxiga (dapagliflozin), an , serves as the cornerstone product, approved for T2D since 2014, with expanded indications for HF with reduced (HFrEF) in 2020, HF with preserved (HFpEF) in 2022, and CKD in 2021, demonstrating reductions in , HF hospitalizations, and CKD progression in trials like DAPA-HF and DAPA-CKD. Farxiga's revenue reached $7,717 million in FY 2024, up 31% at constant exchange rates, driven by label expansions and uptake in cardiorenal indications. Complementary products include Lokelma (), approved for treatment in CKD patients since 2018, which binds potassium in the to normalize serum levels and reduce recurrence risks. Kombiglyze XR (saxagliptin/metformin extended-release), a DPP-4 inhibitor combination for T2D, supports glycemic control but has faced scrutiny over potential HF risks highlighted in SAVOR-TIMI 53 trial data. The CVRM pipeline, updated as of July 29, 2025, comprises over 25 investigational therapies and combinations spanning Phase I to III, focusing on novel targets like aldosterone synthase inhibition, , and dual agonists for and metabolic dysfunction-associated (MASH). Phase III candidates include baxdrostat, an aldosterone synthase inhibitor, which met its primary endpoint in the Bax24 trial on October 7, 2025, achieving a statistically significant reduction in 24-hour ambulatory systolic (approximately 10-15 mmHg) in patients with resistant , with combinations like baxdrostat/dapagliflozin advancing for CKD and HF prevention. Other late-stage assets feature balcinrenone/dapagliflozin for HF with CKD, laroprovstat (AZD0780) for via selective 11β-HSD1 inhibition, and zibotentan/dapagliflozin for high-proteinuria CKD, aiming to regress proteinuria and preserve eGFR. Early-phase efforts target (AZD0233), nephropathy (opemalirsen/AZD2373), and chronic weight management (AZD5004, AZD6234). AstraZeneca integrates and collaborations, such as with BenevolentAI for AI-driven discoveries in HF and CKD, to refine guideline-directed therapies, as showcased in 32 abstracts at the (ESC) Congress 2025, including late-breaking data on HF and outcomes. Initiatives like Healthy Heart Africa have screened over 50 million individuals for since 2014, enhancing access in low-resource settings. The division's strategy prioritizes combination therapies to address multi-organ risks, with ambitions to lead CVRM innovation by 2030 through organ-protective mechanisms beyond symptom management.

Respiratory and Immunology

AstraZeneca's Respiratory and Immunology therapeutic area targets chronic conditions including , (COPD), and , with a strategic emphasis on biologics and inhaled therapies that aim to achieve disease modification rather than mere symptom alleviation. The portfolio generated significant revenue, with biologics like Fasenra contributing $1.7 billion in global sales in 2024, reflecting a 12% increase from the prior year. This focus builds on acquisitions and internal development, prioritizing early intervention and modulation to reduce risks and improve long-term outcomes. Key respiratory products include Symbicort (/formoterol), a fixed-dose approved for maintenance treatment of in patients aged 6 years and older and COPD in adults, which remains a cornerstone despite expiry considerations. Breztri Aerosphere (/glycopyrronium/formoterol fumarate), a triple- therapy, is indicated for COPD maintenance to reduce exacerbations and improve lung function. In May 2025, Trixeo Aerosphere (/glycopyrronium/formoterol fumarate) received approval as the first inhaled COPD therapy utilizing a next-generation with near-zero , marking an environmental advancement in delivery systems. Airsupra (albuterol/), a first-in-class fixed-dose rescue for , addresses acute symptoms with a short-acting beta-agonist and . Biologic therapies dominate severe disease segments. Fasenra (benralizumab), an , is approved for add-on maintenance in severe eosinophilic unresponsive to standard therapies, targeting interleukin-5 receptor alpha to deplete . Tezspire (tezepelumab), co-developed with as a (TSLP) inhibitor, is authorized for severe irrespective of and gained US FDA approval on October 17, 2025, for chronic rhinosinusitis with nasal polyps (CRSwNP) in patients aged 12 and older inadequately controlled by systemic corticosteroids or surgery, supported by Phase 3 data showing reduced polyp burden and nasal congestion. Combined sales of Tezspire by AstraZeneca and totaled $826 million in the first half of 2025, up from $507 million in the same period of 2024, and $1.219 billion for full-year 2024. However, Fasenra's expansion into COPD failed in a Phase 3 trial announced in September 2025, underscoring challenges in broadening indications beyond . In , AstraZeneca pursues therapies to regulate or reset dysregulated immune responses in conditions like systemic lupus erythematosus (SLE). Saphnelo (), a type I , is approved for SLE in adults with moderate to severe disease refractory to standard therapy, demonstrating reductions in disease activity and use in clinical trials. The broader immunology strategy integrates with respiratory efforts, as seen in Tezspire's CRSwNP approval, targeting pathways. The features 196 assets company-wide as of July 2025, with multiple Phase III programs in Respiratory and Immunology, including potential advances in COPD cardiopulmonary risk mitigation and remission strategies presented at the American Thoracic Society conferences in 2024 and 2025.

Rare Diseases and Other Therapeutics

AstraZeneca's rare disease efforts center on the Alexion portfolio, acquired in a $39 billion deal completed on July 21, 2021, which integrated complement biology expertise into its immunology and specialty therapeutics. This acquisition expanded AstraZeneca's capabilities in treating ultra-rare conditions affecting small patient populations, where high unmet needs persist due to limited alternative therapies and complex pathophysiology involving immune dysregulation, enzyme deficiencies, and metabolic disorders. Alexion's foundational products, developed over three decades, target complement-mediated destruction of red blood cells or self-tissues, with subsequent advancements in longer-duration formulations and broader indications. Key approved therapies include Soliris (eculizumab), a inhibiting C5 complement protein, initially approved for (PNH) and later for (aHUS), generalized (gMG), and ; and Ultomiris (ravulizumab), its extended half-life successor offering quarterly dosing, approved for PNH, aHUS, and gMG. Additional products address metabolic rare diseases: Strensiq (asfotase alfa) for (HPP), an enzyme replacement therapy improving skeletal mineralization; Kanuma (sebelipase alfa) for (LAL-D), reducing liver fat accumulation; and Koselugo (selumetinib), a for symptomatic plexiform neurofibromas in pediatric type 1 (NF1). These therapies have demonstrated clinical efficacy in phase 3 trials, such as reduced in PNH patients and improved motor function in gMG, though challenges include high costs—often exceeding $500,000 annually per patient—and risks like meningococcal infections necessitating vaccination. The rare disease pipeline emphasizes diversification beyond complement inhibition, incorporating gene therapies and novel modalities for hematology, neurology, nephrology, and metabolics. In July 2023, Alexion licensed Pfizer's early-stage rare disease gene therapy assets, targeting undisclosed indications with adeno-associated virus vectors to enable one-time treatments. Ongoing programs include subcutaneous formulations of Ultomiris and investigational assets for gMG and lupus nephritis, with data presented at conferences like the 2025 American Academy of Neurology meeting showing advancements in real-world outcomes for rare neurological diseases. However, in February 2025, AstraZeneca discontinued two Alexion-developed candidates following phase 2/3 efficacy shortfalls, reflecting rigorous data-driven decisions amid high failure rates in rare disease development. Beyond rare diseases, AstraZeneca pursues other therapeutics in vaccines and immune therapies, focusing on preventive interventions for infectious diseases outside oncology, cardiovascular, respiratory, and immunology core areas. The portfolio includes monoclonal antibodies and vaccines targeting (RSV) and , addressing annual global burdens of hospitalization in vulnerable populations like infants and the elderly. Notable products are Beyfortus (nirsevimab), a long-acting RSV approved in 2023 to reduce lower respiratory tract infections in infants, and intranasal live attenuated vaccines like Fluenz Tetra, authorized in for children to mitigate seasonal flu severity. These assets leverage antibody engineering for , with indicating up to 70-80% reductions in RSV hospitalizations in trials. Pipeline efforts extend to next-generation prophylactics, prioritizing high-impact pathogens while navigating regulatory hurdles and supply chain demands for scalable biologics.

Financial Performance

Revenue Growth and Profitability Metrics

AstraZeneca's total revenue reached $54,073 million in fiscal year 2024, reflecting a 21% increase at constant exchange rates (CER) from $45,811 million in 2023, primarily driven by 19% CER growth in product sales to $50,938 million. This marked continued expansion, with oncology product sales contributing $22,353 million, up 24% CER and comprising 41% of total revenue. In the first half of 2025, total revenue grew 11% CER to $28,045 million, with product sales up 10% CER to $26,670 million, supported by double-digit CER increases in oncology (15%) and respiratory & immunology (10%). Profitability metrics demonstrated operational efficiency, with core operating profit for FY 2024 at $16,928 million, a 22% CER rise, yielding a of approximately 31%. (EPS) advanced 19% CER to $8.21, while reported EPS increased 29% CER to $4.54. Product sales stood at 81% on a core basis. For H1 2025, core operating profit grew 13% CER, achieving a 33% operating margin, with core EPS up 17% CER to $4.66. The company anticipates high single-digit percentage CER growth in total revenue and low double-digit CER growth in core EPS for FY 2025, consistent with prior guidance. Overall net for trailing twelve months as of mid-2025 was 14.68%, with an of 24.12%.
Fiscal YearTotal Revenue ($ million)CER Growth (%)Core EPS ($)Core Operating Margin (%)
202345,811-7.27-
202454,073218.21
H1 202528,045114.66

Market Position and Shareholder Returns

AstraZeneca ranks among the top global pharmaceutical companies by , reporting trailing twelve-month (TTM) of $56.50 billion as of mid-2025, reflecting a 15% year-over-year increase driven by growth in and other core therapeutic areas. In rankings of leading pharma firms, it placed seventh worldwide by 2024 of $45.8 billion, behind companies such as , , and Merck, with projections for continued expansion toward $80 billion annually by 2030 through new product launches and U.S. investments. By , AstraZeneca holds the fifth position among pharmaceutical companies at approximately $259 billion as of October 2025, underscoring its competitive standing amid industry consolidation and innovation pressures. The company's shares have delivered robust total shareholder returns, with a 61% cumulative return over the five years ending September 2025, combining capital appreciation and dividends. AstraZeneca's grew 7.61% over the prior year to $258.55 billion by late October 2025, supported by strong half-year revenue of $28 billion (up 11%) and of $4.66 (up 17%). Its emphasizes progressive payouts, with the board intending to increase the annual dividend to $3.20 per share for 2025, paid semi-annually and yielding approximately 1.84% based on recent ex-dividend dates. This approach has contributed to compounded annual returns exceeding 11% historically when including reinvested dividends, positioning AstraZeneca as a reliable performer for long-term investors despite sector volatility from patent cliffs and regulatory scrutiny.

Leadership and Governance

Senior Executive Team

The Senior Executive Team (SET) of AstraZeneca, operating under the authority of the , is responsible for developing and executing the company's global strategy, overseeing operations across therapeutic areas, , and key functions such as , , and compliance. The team comprises executives with expertise in pharmaceuticals, , and business management, focusing on innovation in , bioPharmaceuticals, and rare diseases while managing the integration of acquisitions like . Pascal Soriot serves as and Chief Executive Officer, a position he has held since October 2012, leading the SET in transforming AstraZeneca into a science-led company with a emphasis on R&D and advancement. Aradhana Sarin has been and Chief Financial Officer since August 2021, managing financial strategy, , and capital allocation amid the company's expansion in the United States and Europe. Other key members include:
  • Pam Cheng, Executive Vice President of Global Operations, IT, and , overseeing , technology infrastructure, and environmental initiatives.
  • David Fredrickson, Executive Vice-President of the Business Unit, directing commercial strategy for AstraZeneca's largest revenue-generating portfolio.
  • Ruud Dobber, Executive Vice-President of the BioPharmaceuticals Business Unit, responsible for cardiovascular, renal, , respiratory, and products.
  • Marc Dunoyer, of Alexion (a focused on s) and for AstraZeneca, integrating rare disease operations into the broader enterprise.
  • Susan Galbraith, Executive Vice-President of R&D, leading and clinical development in cancer therapies.
  • Sharon Barr, Executive Vice-President of BioPharmaceuticals R&D, advancing research in non-oncology areas.
  • Iskra Reic, Executive Vice-President of International, managing markets outside the and driving global access to medicines.
  • Jeff Pott, , , and , handling , regulatory adherence, and legal affairs.
The SET's composition reflects AstraZeneca's shift toward R&D-intensive growth, with several members having joined or advanced roles post-2012 to support acquisitions and therapeutic expansions, though specific appointment dates for most beyond the CEO and CFO are not publicly detailed in official disclosures.

Board Composition and Corporate Governance

AstraZeneca's consists of 14 members, including two executive directors and 12 , as of October 2025. The board is chaired by Michel Demaré, a appointed to the role in April 2023 following his initial board membership in September 2019. Executive directors include , who has served in that capacity since October 2012, and Aradhana Sarin, appointed in August 2021. The Senior Independent is Philip Broadley, in the position since March 2021 after joining the board in April 2017. The non-executive directors are Euan Ashley (since October 2020), Birgit Conix (since February 2025), (since January 2025), Karen Knudsen (elected at the April 11, 2025, with 99.97% approval), Diana Layfield (since November 2020), Anna Manz (since September 2023), Sheri McCoy (since October 2017), Tony Mok (since January 2019), Nazneen Rahman (since June 2017), and Marcus Wallenberg (since April 1999). Recent appointments reflect board refresh efforts, with Haas and Conix joining in early 2025 to bring expertise in technology and financial services, respectively, while Knudsen's election followed the retirement of Deborah DiSanzo and Andreas Rummelt at the 2025 AGM.
Key Board CommitteesChairMembers (Selected)Primary Purpose
Audit CommitteePhilip BroadleyBirgit Conix, Anna Manz, Sheri McCoyOversees financial reporting, internal controls, and external audit processes.
Remuneration CommitteeSheri McCoyPhilip Broadley, Michel Demaré, Nazneen RahmanDetermines policies and aligns incentives with long-term .
AstraZeneca's corporate governance is led by the board, which holds ultimate responsibility for setting the company's strategy, policies, risk oversight, and monitoring progress against objectives through regular meetings and an annual strategy review. The framework complies with the , with disclosures on deviations where applicable, and accounts for the company's dual listing on Stock Exchange and Nasdaq, requiring alignment with relevant standards as a foreign private issuer. Independence is emphasized, with the majority of non-executive directors classified as independent, though long-tenured members like Wallenberg may face scrutiny under code provisions on tenure limits. The board maintains policies on inclusion and diversity in director selection, overseen by the Nomination and Governance Committee, to ensure a balance of skills in areas such as pharmaceuticals, finance, and technology. Risk management is integrated into board deliberations, with committees providing specialized oversight, and the structure supports accountability to shareholders via annual reports and AGMs.

Regulatory and Political Engagement

Lobbying Efforts and Policy Advocacy

AstraZeneca maintains dedicated government relations teams to influence policy on drug regulation, , pricing, and funding, primarily through direct , trade associations, and legal challenges. In the United States, the company reported federal lobbying expenditures of $3.49 million in 2025 (year-to-date), $3.715 million in 2024, $4.63 million in 2023, and $3.47 million in 2020, focusing on issues such as Medicare drug pricing reforms and FDA approvals. These efforts are channeled via in-house lobbyists and hired firms, targeting congressional committees and agencies to advocate for extended protections and against mandatory price negotiations that could erode returns on R&D investments. A key example of AstraZeneca's US advocacy involved challenging the Inflation Reduction Act's Drug Price Negotiation Program in federal court in 2025, alongside AstraZeneca AB, contending that government-set prices for select Medicare drugs infringe on constitutional protections for innovation incentives. In October 2025, the company reached an agreement with the government to reduce costs for certain medicines while pledging $50 billion in domestic manufacturing and R&D investments by 2030, aligning with administration priorities on amid tariff threats. AstraZeneca's also facilitates employee contributions to federal and state candidates, raising $839,889 in the 2023-2024 election cycle to support aligned policymakers. In , AstraZeneca engages through its office and EU Transparency Register entries, on healthcare access, regulatory data protection, and trade policies, with activities emphasizing opposition to reforms shortening exclusivity periods for new medicines. Company executives, such as Stefan Woxström, have publicly argued that proposed EU pharmaceutical reforms would diminish R&D incentives and , potentially redirecting investments outside the bloc. In the UK, AstraZeneca against a proposed levy on pharmaceutical profits in 2024, warning of job cuts in response to measures aimed at funding restoration through industry contributions. These efforts reflect broader pharmaceutical sector , where AstraZeneca participates in alliances pushing for to sustain high-margin , while committing to tiered policies in low-income countries to balance access and profitability.

Government Contracts and International Relations

AstraZeneca entered into substantial advance purchase agreements with multiple governments for its COVID-19 vaccine candidate, AZD1222 (later Vaxzevria), developed in collaboration with the . In May 2020, the government signed a contract with AstraZeneca for up to 100 million doses, supported by an initial £65.5 million commitment for and , with the company agreeing to supply at cost and on a "best efforts" basis. This agreement prioritized supply, as it predated similar deals elsewhere and included provisions allowing use of EU-manufactured doses if needed. The , on behalf of EU member states, finalized a in 2020 for up to 400 million doses, with an initial commitment for 300 million, also at no profit for the company during the . Delivery shortfalls in early 2021 prompted legal action by the EU against AstraZeneca, which the company contested by citing contractual obligations to earlier agreements like the UK's and manufacturing constraints at EU sites; the dispute highlighted ambiguities in supply sequencing and export reporting requirements. In the United States, AstraZeneca pursued manufacturing partnerships rather than direct vaccine procurement contracts, including a $174 million agreement in 2020 with for AZD1222 production, building on an initial $87 million contract, under . Separate U.S. government deals covered the company's cocktail AZD7442 (), with modifications in March 2021 to supply up to 500,000 additional doses. These arrangements focused on domestic production scaling to support national emergency responses. Beyond COVID-19, AstraZeneca has engaged in broader government and supply pacts. In October 2025, the company reached a voluntary agreement with the U.S. government under the Trump administration to implement most-favored-nation (MFN) , aligning U.S. costs with lower international rates for select medicines, while committing $50 billion in U.S.-based manufacturing and R&D investments to enhance domestic sourcing and reduce tariff exposures. This deal, the second such MFN arrangement for AstraZeneca, aimed to lower prescription costs for American patients without invoking statutory . Internationally, AstraZeneca's contracts have influenced diplomatic tensions, particularly during the supply dispute, where export controls from plants to the and other nations underscored post-Brexit frictions in pharmaceutical supply chains. The company maintains ongoing public-private alliances with governments and organizations like and the for equitable vaccine access in lower-income countries, often at concessional terms. These engagements reflect AstraZeneca's dual role in national security-driven procurement and equity initiatives.

COVID-19 Vaccine Program

Development and Clinical Trials

The AZD1222 vaccine (also known as nCoV-19 or Vaxzevria/Covishield) was developed through a collaboration between the University of 's Jenner Institute and AstraZeneca, leveraging 's prior research on chimpanzee adenovirus () vectors for vaccines against pathogens like Middle East respiratory syndrome coronavirus (MERS-CoV).31604-4/fulltext) Work on adapting the platform for began in January 2020, shortly after the virus's genetic sequence was published, with preclinical studies in animal models demonstrating immunogenicity and protection against viral challenge by March 2020. On April 30, 2020, AstraZeneca entered a binding agreement with to fund, manufacture, and distribute up to 2 billion doses globally at no profit during the pandemic, committing to equitable access via mechanisms like . Phase 1/2 clinical trials commenced in the in late 2020 across five sites, enrolling 543 healthy adults aged 18-55 in a single-blind, randomized, controlled study to evaluate , , and optimal dosing of the two-dose regimen (standard dose of 5×10^10 viral particles each, administered 28 days apart).31604-4/fulltext) Initial results, published July 20, 2020, confirmed the vaccine's tolerability, with mild-to-moderate reactogenicity (e.g., local pain, , feverishness) peaking after the first dose and resolving within days; it elicited strong T-cell and neutralizing responses in over 90% of participants, comparable to convalescent plasma levels.31604-4/fulltext) A subsequent analysis in December 2020 showed enhanced without increased concerns. Phase 3 trials expanded globally, pooling data from randomized, double-blind, placebo-controlled studies in the UK (initiated May 2020, NCT04400838) and Brazil (initiated June 2020, NCT04444674), involving over 11,000 participants aged 18 and older, with interim efficacy analysis on November 23, 2020, reporting 70.4% overall efficacy against symptomatic COVID-19 (95% CI: 54.8-80.6), rising to 90% (67.0-97.0) in a subgroup receiving a lower first dose due to an inadvertent manufacturing variation, and 100% prevention of severe disease or hospitalization.32661-1/fulltext) A separate U.S. Phase 3 trial (NCT04516746) began enrollment on August 31, 2020, targeting approximately 30,000 adults at 80 sites to assess efficacy in diverse populations, including older adults and those with comorbidities, with primary endpoint of preventing COVID-19 disease. Full pooled Phase 3 data published in December 2020 confirmed consistent safety (no vaccine-related hospitalizations) and efficacy across age groups, though reactogenicity remained higher after the first dose.32661-1/fulltext) An independent data monitoring committee verified no increased thrombosis risk in early analyses, supporting progression to regulatory submissions.

Efficacy, Safety, and Real-World Data

The phase 3 of AZD1222 ( nCoV-19), conducted across 88 sites , , and with 32,451 participants, demonstrated (95% CI, 65.3-80.5) against symptomatic occurring 15 or more days after the second dose. was 83.5% (95% CI, 54.2-94.1) among participants aged 65 years and older and 72.8% (95% CI, 63.4-79.9) among those aged 18-64 years. Against severe or critical and hospitalizations, efficacy reached 100% (no cases among 17,662 vaccinated participants versus 8 cases among 8,550 recipients), with 94.2% efficacy specifically against hospitalization (95% CI, 53.3-99.3). In trial safety data, adverse events were predominantly mild to moderate, with serious adverse events occurring in 0.5% of vaccinated participants, comparable to the group (0.5%); no vaccine-related deaths were reported, and with was observed at low incidence. Post-authorization surveillance identified rare but serious adverse events, including thrombosis with thrombocytopenia syndrome (TTS), characterized by blood clots and low platelet counts. The (EMA) reported approximately 900 TTS cases following Vaxzevria vaccination up to May 2023, with around 200 fatalities, classifying TTS as a very rare event. Guillain-Barré syndrome (GBS) was also confirmed as very rare, with an incidence below 1 in 10,000 vaccinated individuals, potentially leading to or respiratory issues. These risks prompted regulatory recommendations in some jurisdictions to prioritize Vaxzevria for older adults, where benefits against severe disease outweighed the low absolute risks observed primarily in younger populations. Real-world studies corroborated high protection against severe outcomes. A test-negative case-control analysis in found vaccine effectiveness (VE) exceeding 93% against Delta variant hospitalization across age groups, with robust results (>98% in some endpoints) for adults aged 18-64 and 65+. For , VE against hospitalization was 75-80% (up to 93% for severe endpoints requiring oxygen) in adults aged 18-64 shortly after dosing, waning to 38-69% after 15+ weeks; in those 65+, VE remained 86-95% initially and above 80% long-term. Effectiveness against infection waned more substantially with variants like compared to original strains or Delta, but protection against hospitalization and death stayed strong, often 80-90% in meta-analyses of observational data from diverse populations. These findings, derived from large-scale health records, aligned with trial data on severe disease prevention while highlighting variant-specific reductions in mild infection blockade.

Global Rollout and Public Health Impact

The AstraZeneca , known as Vaxzevria in and Covishield in , received initial emergency authorization in the on December 30, 2020, marking the start of its global distribution. The granted emergency use listing on February 15, 2021, facilitating rollout through the initiative to over 140 low- and middle-income countries. By mid-2021, authorizations expanded to more than 170 countries, with AstraZeneca establishing manufacturing partnerships in , , and elsewhere to produce over 2 billion doses, prioritizing equitable access in regions with limited alternatives. Production scaled rapidly, supplying vaccines at cost price to 97% of participating nations via , though disruptions and variant surges delayed full deployment in some areas. Real-world data demonstrated substantial benefits, particularly in preventing severe and death. Modeling analyses estimated the vaccine averted 6.3 million deaths globally in its first year of rollout (December 2020 to December 2021), outperforming other vaccines in reach to lower-income settings where it comprised a majority of doses administered. Studies in diverse populations showed 76-90% effectiveness against hospitalization from Alpha and Delta variants after two doses, with a single dose reducing severe outcomes by 82% across variants including Beta. Against , booster dosing with Vaxzevria yielded 73% protection from infection and high efficacy against severe , contributing to reduced mortality in high-burden regions like and . Safety monitoring across billions of doses identified rare adverse events, including thrombosis with thrombocytopenia syndrome (TTS) at rates of approximately 1 in 50,000 to 100,000 recipients, primarily in younger adults after the first dose. Global studies in eight countries confirmed these events but affirmed the vaccine's favorable risk-benefit profile, with benefits in mortality reduction far exceeding risks, especially in older or high-risk groups. By 2024, as demand waned with updated vaccines, AstraZeneca withdrew marketing authorizations in the in March and globally in May, shifting focus to other therapeutics.

Associated Controversies and Responses

In early 2021, reports emerged of rare cases of thrombosis with thrombocytopenia syndrome (TTS), characterized by blood clots and low platelet counts, following administration of Vaxzevria (AstraZeneca's ). The (EMA) reviewed 86 confirmed cases across the by April 7, 2021, primarily in women under 60, concluding a possible causal link and listing TTS as a very rare side effect, with an incidence of approximately 8 cases per million doses overall and higher (up to 1 in 10,000) in younger women. Similar events prompted temporary pauses in vaccine use in several countries, including , and , amid investigations by bodies like the UK's Medicines and Healthcare products Regulatory Agency (MHRA), which identified 30 TTS cases by April 2021, including 7 deaths. The World Health Organization's Global Advisory Committee on Vaccine Safety assessed the risk as very low, around 4-6 cases per million doses based on UK and European data, emphasizing that TTS rates were lower than those from infection itself. AstraZeneca initially stated on March 18, 2021, that there was "no evidence of an increased risk of or " beyond background rates, attributing events to coincidental factors. However, by February 2024, in response to a class-action lawsuit involving 51 claimants alleging TTS-related injuries or deaths, AstraZeneca conceded in legal documents that Vaxzevria "can, in very rare cases, cause TTS," marking the first formal admission of causation, though the company maintained the risk was extremely low and benefits outweighed harms during the . Claimants, including relatives of deceased patients and survivors with severe disabilities like injuries, seek potentially exceeding £100 million; the case, consolidated under a group litigation order, argues failures in warning labels and assurances. A 2023 BMJ report detailed affected individuals, such as a music promoter who suffered a hemorrhage post-vaccination in April 2021, highlighting catastrophic outcomes in rare instances despite millions of safe doses administered globally. Additional scrutiny arose over Vaxzevria's efficacy profile compared to mRNA vaccines, with initial phase 3 trials reporting 76% efficacy against symptomatic in updated (as of December 2020), lower than Pfizer-BioNTech's 95% and Moderna's 94.1%, fueling debates on dosing intervals and variant performance. Real-world studies later affirmed 70-92% effectiveness against hospitalization and death, particularly pre-Delta variant, but lower infection prevention (around 70%) versus mRNA options (85-95%), prompting some authorities to prioritize alternatives for younger groups where TTS risk-benefit skewed. AstraZeneca responded by affirming equivalent protection against severe outcomes in head-to-head analyses with mRNA vaccines, citing 79 real-world studies showing comparable hospitalization reduction (77-93% for mRNA vs. 70-85% for Vaxzevria at 4-6 months post-vaccination). Regulators like the EMA reiterated on March 18, 2021, that benefits exceeded risks, especially in high-transmission settings, leading to continued authorization with updated warnings; by 2024, AstraZeneca withdrew European marketing authorization for commercial reasons—shift to variant-adapted vaccines—while defending overall safety in ongoing litigation.

Other Major Controversies

Drug Marketing and Pricing Disputes

In April 2010, AstraZeneca agreed to pay $520 million to settle allegations by the U.S. Department of Justice that it had illegally promoted its antipsychotic drug Seroquel () for off-label uses, including in the elderly and aggression or ADHD in children, between 2001 and 2007. The settlement resolved False Claims Act violations stemming from a whistleblower , with AstraZeneca neither admitting nor denying the claims but entering into a corporate integrity agreement to oversee future marketing practices; the whistleblower received over $45 million. This followed internal documents showing sales representatives were incentivized to pitch unapproved uses despite known risks, such as increased mortality in elderly patients, leading to reimbursements under federal healthcare programs for non-FDA-approved indications. Additional state-level resolutions included a 2011 agreement for AstraZeneca to pay $68.5 million to 37 states and the District of Columbia over improper Seroquel marketing, marking a record at the time for such cases, with claims centered on deceptive promotion to homes and pediatric populations. In 2018, AstraZeneca settled fraud allegations with for $110 million, addressing overpayments for drugs including Seroquel promoted off-label or with misleading safety data to influence prescribing. These cases highlight patterns where prioritized volume over label restrictions, contributing to cumulative penalties exceeding $500 million for Seroquel-related misconduct, though AstraZeneca maintained the promotions were educational rather than promotional. On pricing, AstraZeneca has contested U.S. government efforts to curb drug costs, notably challenging the Inflation Reduction Act's (IRA) Medicare Drug Price Negotiation Program in lawsuits filed in 2023. The company argued the program imposes unconstitutional price controls on small-molecule drugs like its cancer treatments, violating by depriving property rights to set market prices and limiting under the . Federal courts, including the Third Circuit in May 2025, rejected these claims, affirming the program's validity as it applies only to selected high-cost Medicare drugs after patent exclusivity periods. AstraZeneca petitioned the U.S. in September 2025 to review the decision, asserting broader implications for innovation incentives. Separately, in May 2025, it settled a class-action antitrust suit for $50.9 million over alleged pay-for-delay deals delaying generic Seroquel XR competition, without admitting liability.

Clinical Data and Trial Integrity Issues

AstraZeneca's (marketed as Brilinta), approved in 2011 for reducing cardiovascular events, has faced scrutiny over data integrity in pivotal trials like , which enrolled over 18,000 patients and demonstrated superiority over clopidogrel. A June 2025 investigation uncovered serious misreporting, including duplicated patient data, implausible event timings, and discrepancies between clinical study reports and publications, raising doubts about the trial's validity and the drug's approval basis. These irregularities extended to three trials supporting 's indications, with missing laboratory readings and inconsistent classifications potentially undermining safety assessments. The trial's data issues, highlighted in a December 2024 analysis, involved mismatched randomization dates and event logs that suggested post-hoc alterations, eroding confidence in the reported 16% for cardiovascular death, MI, or stroke. Independent reanalysis by the team identified over 100 anomalies in source documents obtained via requests, prompting calls for regulatory re-evaluation despite AstraZeneca's defense that the data supported real-world benefits. Critics, including trial statisticians, argued these flaws could indicate selective reporting favoring , though no of fabrication was proven; the findings underscore broader concerns about transparency in industry-sponsored trials. In the context of the Oxford-AstraZeneca COVID-19 vaccine (Vaxzevria), March 2021 interim Phase 3 data submission to U.S. regulators drew criticism for relying on outdated information, reporting only 21 symptomatic cases from November 2020 rather than 32 from updated February 2021 datasets, which overstated efficacy at 79% versus the later confirmed 76%. U.S. health officials, including the NIH and FDA, publicly questioned the data's completeness and timeliness, halting discussions and highlighting risks of premature release amid global pressure. AstraZeneca responded by submitting fuller datasets, but the episode eroded trust, with data safety monitoring boards noting inconsistencies in event adjudication across U.K. and U.S. cohorts. Historical precedents include AstraZeneca's 2010 settlement of $520 million with the U.S. Department of Justice over Seroquel () marketing, which incorporated a corporate integrity agreement mandating enhanced oversight of promotion, though core allegations centered on rather than trial fabrication. Subsequent audits revealed instances of misleading trial interpretations in promotional materials, but primary trial was not formally impugned. These cases illustrate recurring patterns of data handling lapses, often addressed via fines without invalidating approvals, yet prompting demands for stricter independent verification in pharmaceutical research.

Ethical Concerns in International Operations

AstraZeneca's international operations have faced scrutiny over allegations of improper payments to influence healthcare providers in emerging markets, particularly in China and Russia. In August 2016, the U.S. Securities and Exchange Commission (SEC) charged AstraZeneca with violations of the Foreign Corrupt Practices Act (FCPA) due to actions by its wholly-owned subsidiaries between 2007 and 2011. In China, subsidiary employees provided luxury travel, entertainment, and gifts to doctors at state-owned hospitals to induce prescriptions of AstraZeneca drugs, including cash equivalents disguised as speaker fees at sham conferences; these practices generated approximately $7 million in improper benefits. In Russia, similar schemes involved funding overseas education for healthcare professionals and their families, as well as cash payments, to boost sales of the antipsychotic Seroquel, yielding about $10.8 million in tainted revenue. AstraZeneca settled the SEC matter by paying $5.5 million, including disgorgement and penalties, without admitting or denying the findings, while the U.S. Department of Justice closed its parallel inquiry in November 2016. These incidents highlighted deficiencies in internal controls and compliance programs in high-corruption-risk environments, where interactions with government-employed doctors created incentives for bribery. More recently, AstraZeneca's operations in have been subject to multiple government investigations amid Beijing's broader campaign in the healthcare sector. In September 2024, Chinese authorities detained five current and former employees as part of a probe into medical , with reports implicating dozens of senior executives in schemes to manipulate reimbursements, potentially involving falsified claims for drugs like the breast Enhertu. Separate inquiries, ongoing as of early 2025, examined allegations of illegal importation of unapproved drugs, evasion of over $1.6 million in import taxes, and unauthorized on patients. AstraZeneca's China President, Leon Wang, was placed under investigation in October 2024 for these matters, though the company stated the issues were unrelated to its core business practices and emphasized cooperation with authorities. These probes contributed to an 8-10% drop in AstraZeneca's share price in late 2024, reflecting investor concerns over regulatory risks in China's opaque enforcement environment, where foreign firms often face heightened scrutiny amid national priorities like cost control in healthcare spending. Such cases underscore persistent challenges in AstraZeneca's global compliance framework, particularly in jurisdictions with weak rule-of-law protections and where pharmaceutical sales rely heavily on relationships with state-influenced entities. While AstraZeneca maintains a zero-tolerance policy on and has enhanced training and auditing post-2016, critics argue that aggressive expansion in markets like —where it derives significant revenue—exposes the firm to ethical lapses driven by sales pressures. No major ethical controversies have been publicly resolved regarding conduct in developing countries, though general industry concerns about and post-trial access persist in outsourced studies.

References

  1. https://www.astrazeneca.com/our-company.html
  2. https://www.astrazeneca.com/our-company/history.html
  3. https://www.astrazeneca.com/our-therapy-areas.html
  4. https://synapse.patsnap.com/article/what-are-the-top-selling-drugs-of-astrazeneca
  5. https://www.astrazeneca.com/our-therapy-areas/pipeline.html
  6. https://www.science.org/content/article/astrazeneca-lowers-efficacy-claim-covid-19-vaccine-bit-after-boards-rebuke
  7. https://pmc.ncbi.nlm.nih.gov/articles/PMC8566665/
  8. https://www.nature.com/articles/s41598-024-75833-z
  9. https://www.tandfonline.com/doi/full/10.1080/10410236.2023.2171951
  10. https://www.fundinguniverse.com/company-histories/astrazeneca-plc-history/
  11. https://pharmaphorum.com/views-analysis-sales-marketing/a_history_of-_astrazeneca
  12. https://www.govinfo.gov/content/pkg/FR-1999-03-30/pdf/99-7752.pdf
  13. https://www.bccresearch.com/company-index/profile/astrazeneca/history
  14. https://ec.europa.eu/competition/mergers/cases/decisions/m1403_en.pdf
  15. https://www.ftc.gov/news-events/news/press-releases/1999/03/merger-zeneca-astra-two-significant-suppliers-pharmaceuticals-cleared-conditions
  16. https://www.astrazeneca.com/investor-relations/faqs.html
  17. https://www.bioworld.com/articles/541952-merger-of-astra-and-zeneca-now-officially-completed
  18. https://ddd.uab.cat/pub/infanu/40172/iaASTZENa1999ieng.pdf
  19. https://www.astrazeneca.com/media-centre/press-releases/2012/AstraZeneca-and-Pfizer-enter-agreement-for-over-the-counter-NEXIUM-AstraZeneca-raises-2012-guidance-13082012.html
  20. https://www.astrazeneca.com/content/dam/az/Investor_Relations/annual-reports-homepage/2004-Annual-Report-English.pdf
  21. https://companiesmarketcap.com/astrazeneca/revenue/
  22. https://www.astrazeneca.com/content/dam/az/Investor_Relations/annual-reports-homepage/2006_Annual_Report-English.pdf
  23. https://dcfmodeling.com/blogs/history/azn-history-mission-ownership
  24. https://europa.eu/rapid/press-release_IP-05-737_en.htm
  25. https://www.antitrustlawblog.com/2005/07/articles/uncategorized/astrazeneca-fined-73m-by-european-commission-for-misuse-of-european-patent-rules/
  26. https://www.cafc.uscourts.gov/opinions-orders/06-1254.pdf
  27. https://www.canlii.org/en/ca/scc/doc/2006/2006scc49/2006scc49.html
  28. https://www.marketwatch.com/story/astrazeneca-reportedly-risks-38-revenue-decline-on-expiring-patents
  29. https://gabionline.net/generics/general/The-biggest-US-patent-expiries-of-2010
  30. https://www.bmj.com/content/344/bmj.e2099
  31. https://www.bbc.com/news/business-21272878
  32. https://www.bloomberg.com/news/articles/2012-03-29/astrazeneca-wins-ruling-on-extended-release-seroquel-patent-1-
  33. https://cen.acs.org/articles/90/i50/Beyond-Patent-Cliff.html
  34. https://globalnews.ca/news/386463/astazeneca-warns-over-expiring-patents-as-net-profit-falls-37-per-cent-to-6-3b/
  35. https://www.astrazeneca.com/content/dam/az/Investor_Relations/annual-reports-homepage/2012-Annual-report-English.pdf
  36. https://medcitynews.com/2013/03/astrazeneca-shakes-up-rd-division-with-1600-staff-cuts-and-focusing-on-biotech-hotspots-video/
  37. https://www.usatoday.com/story/money/business/2013/03/21/astrazeneca-cuts/2005357/
  38. https://www.spglobal.com/marketintelligence/en/mi/country-industry-forecasting.html?id=1065977437
  39. https://www.astrazeneca.com/media-centre/press-releases/2013/astrazeneca-new-global-research-development-centre-corporate-headquarters-cambridge-uk-18062013.html
  40. https://www.bbc.com/news/uk-england-cambridgeshire-25003507
  41. https://www.fiercepharma.com/financials/updated-astrazeneca-steps-up-its-global-restructuring-550-new-job-cuts
  42. https://www.biopharmadive.com/news/AstraZeneca-job-cuts-700/432087/
  43. https://www.astrazeneca.com/media-centre/press-releases/2014/astrazeneca-board-rejects-pfizers-final-proposal-19052014.html
  44. https://www.bbc.com/news/business-27572986
  45. https://www.reuters.com/article/business/pfizer-walks-away-from-118-billion-astrazeneca-takeover-fight-idUSKBN0E70D5/
  46. https://cen.acs.org/articles/93/web/2015/02/AstraZeneca-Spin-Off-Antibiotics.html
  47. https://www.reuters.com/article/business/astrazeneca-sells-rights-to-anesthetics-for-up-to-770-million-idUSKCN0YV0H9/
  48. https://www.ema.europa.eu/en/news/covid-19-vaccine-astrazeneca-benefits-still-outweigh-risks-despite-possible-link-rare-blood-clots-low-blood-platelets
  49. https://www.ema.europa.eu/en/news/astrazenecas-covid-19-vaccine-ema-finds-possible-link-very-rare-cases-unusual-blood-clots-low-blood-platelets
  50. https://www.pharmaceutical-technology.com/news/astrazeneca-admits-covid-19-vaccine-may-cause-blood-clots-in-very-rare-cases/
  51. https://pmc.ncbi.nlm.nih.gov/articles/PMC9055170/
  52. https://www.astrazeneca.com/content/dam/az/PDF/2021/full-year/Full-year-2021-results-announcement.pdf
  53. https://www.biopharmadive.com/news/astrazeneca-withdraw-vaxzevria-covid-19-vaccine/715488/
  54. https://www.astrazeneca.com/content/dam/az/PDF/2024/fy/Full-year-and-Q4-2024-results-announcement.pdf
  55. https://www.statista.com/statistics/293056/astrazeneca-revenue-by-therapeutic-area/
  56. https://www.astrazeneca.com/content/dam/az/PDF/2025/h1q2/H1-and-Q2-2025-results-announcement.pdf
  57. https://www.cnbc.com/2024/05/21/astrazeneca-to-boost-revenue-release-new-medicines-by-2030.html
  58. https://www.astrazeneca.com/media-centre/press-releases/2012/AstraZeneca-to-acquire-Ardea-Biosciences-for-1-billion-23042012.html
  59. https://www.astrazeneca.com/media-centre/press-releases/2013/astrazeneca-bristol-myers-squibb-global-diabetes-alliance-assets-19122013.html
  60. https://www.astrazeneca.com/media-centre/press-releases/2015/AstraZeneca-strengthens-Cardiovascular-and-Metabolic-disease-portfolio-with-acquisition-of-ZS-Pharma-06112015.html
  61. https://www.astrazeneca.com/media-centre/press-releases/2016/astrazeneca-completes-transaction-for-majority-equity-stake-investment-in-acerta-pharma-01022016.html
  62. https://www.astrazeneca.com/media-centre/press-releases/2020/astrazeneca-to-acquire-alexion.html
  63. https://www.astrazeneca.com/media-centre/press-releases/2021/acquisition-of-alexion-completed.html
  64. https://www.astrazeneca.com/media-centre/press-releases/2024/astrazeneca-to-acquire-fusion.html
  65. https://www.astrazeneca.com/media-centre/press-releases/2024/acquisition-of-gracell-completed.html
  66. https://www.astrazeneca.com/media-centre/press-releases/2024/astrazeneca-completes-acquisition-of-icosavax.html
  67. https://www.astrazeneca.com/media-centre/press-releases/2024/astrazeneca-to-acquire-amolyt.html
  68. https://www.biospace.com/business/astrazeneca-makes-potential-1b-cell-therapy-play-in-esobiotec-buy
  69. https://www.biopharmadive.com/news/astrazeneca-sells-off-more-non-core-assets-raising-nearly-600m/414801/
  70. https://www.biopharmadive.com/news/astrazeneca-sells-us-rights-to-4-non-core-drugs/513885/
  71. https://www.astrazeneca.com/media-centre/press-releases/2012/AstraZenecas-new-restructuring-initiatives-to-drive-productivity-and-support-innovation-02022012.html
  72. https://www.fiercepharma.com/manufacturing/astrazeneca-aims-to-streamline-manufacturing
  73. https://firstwordpharma.com/story/4281470
  74. https://www.globaldata.com/company-profile/astrazeneca-plc/locations/
  75. https://www.pharmaceutical-technology.com/projects/astrazeneca-cambridge/
  76. https://www.astrazeneca.com/our-company/leadership.html
  77. https://www.astrazeneca.com/our-company/our-people.html
  78. https://www.astrazeneca.com/investor-relations/corporate-governance.html
  79. https://www.weforum.org/organizations/astrazeneca/
  80. https://www.astrazeneca.com/media-centre/press-releases/2024/astrazeneca-to-manufacture-adcs-in-singapore.html
  81. https://www.astrazeneca-us.com/media/press-releases/2025/AstraZeneca-plans-to-invest-50-billion-in-America-for-medicines-manufacturing-and-R-and-D.html
  82. https://www.governor.virginia.gov/newsroom/news-releases/2025/october/name-1063825-en.html
  83. https://www.astrazeneca-us.com/media/press-releases/2025/astrazeneca-plans-to-increase-investment-and-scope-of-its-virginia-manufacturing-facility-to-four-point-five-billion-creating-thirty-six-hundred-new-jobs.html
  84. https://www.reuters.com/sustainability/boards-policy-regulation/astrazeneca-unveils-50-billion-us-investment-pharma-tariff-threat-looms-2025-07-21/
  85. https://careers.astrazeneca.com/apicomdublin
  86. https://careers.astrazeneca.com/mexico
  87. https://www.astrazeneca.com/media-centre/articles/2024/global-operations-digital-ai-wef-lighthouse.html
  88. https://scw-mag.com/news/inside-astrazenecas-dual-supply-chain-approach/
  89. https://www.astrazeneca.com/content/dam/az/Sustainability/Sustainable-Use-and-Sourcing-of-Raw-Materials.pdf
  90. https://sciencebasedtargets.org/companies-taking-action/case-studies/supplier-engagement-case-study-astrazeneca
  91. https://www.astrazeneca.com/content/dam/az/Investor_Relations/annual-report-2023/pdf/AstraZeneca_Risk_Supplement_2023.pdf
  92. https://www.astrazeneca.ch/en/innovating-production-and-manufacture-to-meet-the-challenge-of-covid-19.html
  93. https://www.astrazeneca-us.com/media/press-releases/2023/astrazeneca-to-leverage-its-global-industrial-scale-manufacturing-and-digital-capabilities-to-boost-us-renewable-natural-gas-productivity.html
  94. https://www.linkedin.com/posts/omp-supply-chain-planning_how-astrazeneca-is-driving-innovation-agility-activity-7275876105096425473-I9ve
  95. https://www.reuters.com/business/healthcare-pharmaceuticals/astrazeneca-to-invest-15-bln-china-through-2030-2026-01-29/
  96. https://www.pharmtech.com/view/astrazeneca-us-expansion-highlights-ai-automation-policy-pressure-pharma-manufacturing
  97. https://www.pharmamanufacturing.com/industry-news/news/55323673/astrazeneca-doubles-texas-production-capacity-with-445m-facility-expansion
  98. https://www.astrazeneca.com/media-centre/press-releases/2024/astrazeneca-invests-3bn-500mn-in-us.html
  99. https://www.reuters.com/business/healthcare-pharmaceuticals/astrazeneca-pauses-270-million-investment-britain-2025-09-12/
  100. https://www.macrotrends.net/stocks/charts/AZN/astrazeneca/research-development-expenses
  101. https://www.fiercebiotech.com/special-reports/top-10-pharma-rd-budgets-2024
  102. https://www.astrazeneca.com/content/dam/az/Investor_Relations/annual-report-2024/pdf/AstraZeneca_AR_2024.pdf
  103. https://www.drugdiscoverytrends.com/top-25-investors-in-pharma-rd-in-2024/
  104. https://www.astrazeneca.com/r-d.html
  105. https://www.astrazeneca.com/r-d/our-approach.html
  106. https://www.astrazeneca-us.com/content/dam/az-us/Documents/AstraZeneca-in-the-US.pdf
  107. https://www.astrazeneca.com/media-centre/press-releases/2025/astrazeneca-invests-2-and-half-bn-in-beijing-r-and-d-and-manufacturing.html
  108. https://www.astrazeneca.com/r-d/next-generation-therapeutics.html
  109. https://www.fiercebiotech.com/biotech/astrazeneca-building-transparent-pipeline-ground
  110. https://www.astrazeneca.com/our-therapy-areas/oncology/medicines-portfolio-and-pipeline.html
  111. https://www.astrazeneca-us.com/media/press-releases/2025/astrazeneca-to-showcase-latest-research-on-comprehensive-portfolio-and-pipeline-aimed-at-transforming-respiratory-diseases-at-ATS-2025.html
  112. https://trial.medpath.com/news/4262d07cad88a586/astrazeneca-reports-robust-21-revenue-growth-in-2024-projects-strong-pipeline-momentum-for-2025
  113. https://www.astrazeneca.com/content/dam/az/PDF/2025/h1q2/H1-and-Q2-2025-results-clinical-trials-appendix.pdf
  114. https://www.astrazeneca.com/partnering.html
  115. https://www.astrazeneca.com/partnering/our-areas-of-partnering-interest.html
  116. https://www.astrazeneca.com/our-company/our-locations/gothenburg.html
  117. https://azbioventurehub.com/
  118. https://www.astrazeneca.com/media-centre/press-releases/2020/astrazeneca-and-daiichi-sankyo-enter-collaboration-to-develop-and-commercialise-new-antibody-drug-conjugate.html
  119. https://www.tempus.com/news/tempus-signs-expanded-strategic-agreements-with-astrazeneca-and-pathos-to-develop-the-largest-multimodal-foundation-model-in-oncology/
  120. https://ir.sophiagenetics.com/2025-09-22-SOPHiA-GENETICS-Expands-Collaboration-with-AstraZeneca-to-Enhance-Detection-of-Breast-and-Prostate-Cancer
  121. https://investors.danaher.com/2025-05-29-Danaher-Announces-Diagnostic-Development-and-Commercialization-Partnership-to-Scale-Precision-Medicine
  122. https://www.astrazeneca.com/media-centre/press-releases/2023/astrazeneca-cell-and-gene-therapy-deal-w-cellectis.html
  123. https://cepi.net/cepi-and-astrazeneca-advance-discovery-novel-antibody-help-prevent-infection-during-outbreaks
  124. https://www.pharmexec.com/view/astrazeneca-cspc-launch-ai-powered-collaboration-oral-drug-discovery
  125. https://www.astrazeneca.com/partnering/why-partner-with-astrazeneca.html
  126. https://www.nasdaq.com/articles/astrazeneca-rides-oncology-momentum-blockbuster-and-new-drugs
  127. https://www.drugdiscoverytrends.com/top-25-drugs-by-sales-2025-h1/
  128. https://xtalks.com/top-50-best-selling-drugs-to-watch-in-2025-insights-from-2024-sales-data-4343/
  129. https://www.oncnursingnews.com/view/oncology-drugs-approved-by-the-fda-in-january-2025
  130. https://www.astrazeneca.com/media-centre/articles/2024/oncology-r-and-d-strategy-driving-innovation.html
  131. https://www.astrazeneca.com/our-therapy-areas/cardiovascular-renal-and-metabolism.html
  132. https://www.astrazeneca.com/content/dam/az/PDF/2024/fy/Full-year-and-Q4-2024-results-presentation.pdf
  133. https://www.astrazeneca.com/media-centre/articles/astrazeneca-at-esc.html
  134. https://www.astrazeneca-us.com/medicines/astrazeneca-medications.html
  135. https://www.astrazeneca-us.com/media/press-releases/2025/Baxdrostat-met-the-primary-endpoint-in-Bax24-Phase-III-trial-in-patients-with-resistant-hypertension.html
  136. https://www.fiercepharma.com/pharma/astrazenecas-fasenra-comes-short-again-copd
  137. https://www.astrazeneca.com/our-therapy-areas/respiratory-and-immunology.html
  138. https://www.astrazeneca.com/content/dam/az/Investor_Relations/annual-report-2024/pdf/AstraZeneca_Patent_Expiries_of_Key_Marketed_Products_2024.pdf
  139. https://www.astrazeneca.com/media-centre/press-releases/2025/trixeo-aerosphere-approved-in-the-uk-as-first-inhaled-respiratory-medicine-using-next-generation-propellant-with-near-zero-global-warming-potential.html
  140. https://firstwordpharma.com/story/6324607
  141. https://www.astrazeneca.com/our-therapy-areas/respiratory-and-immunology/immunology.html
  142. https://www.astrazeneca.com/our-therapy-areas/rare-disease.html
  143. https://alexion.com/rare-disease-research-and-development
  144. https://alexion.com/our-medicines
  145. https://www.astrazeneca.com/media-centre/press-releases/2023/alexion-enters-gene-therapy-agreement-with-pfizer.html
  146. https://www.astrazeneca-us.com/media/press-releases/2025/Alexion-data-presented-at-the-2025-AAN-Annual-Meeting-highlight-advancements-in-improving-care-for-rare-neurological-diseases.html
  147. https://www.biospace.com/business/astrazeneca-axes-two-alexion-assets-as-q4-earnings-exceed-expectations
  148. https://www.astrazeneca.com/our-therapy-areas/vaccines-and-immune-therapies.html
  149. https://finance.yahoo.com/quote/AZN/key-statistics/
  150. https://www.proclinical.com/blogs/2024-7/who-are-the-top-10-pharma-companies-in-the-world-2025
  151. https://companiesmarketcap.com/pharmaceuticals/largest-pharmaceutical-companies-by-market-cap/
  152. https://companiesmarketcap.com/astrazeneca/marketcap/
  153. https://finance.yahoo.com/news/astrazenecas-lon-azn-investors-pleased-071259846.html
  154. https://stockanalysis.com/stocks/azn/market-cap/
  155. https://www.crispidea.com/pharma-stocks-2025-pfizer-novartis-astrazeneca/
  156. https://stockanalysis.com/stocks/azn/dividend/
  157. https://dividendstocks.cash/dividend-profile/AstraZeneca-Dividend
  158. https://craft.co/astrazeneca/executives
  159. https://www.globaldata.com/company-profile/astrazeneca-plc/executives/
  160. https://www.comparably.com/companies/astrazeneca-plc/executive-team
  161. https://www.astrazeneca.com/content/dam/az/PDF/2025/Results-of-Annual-General-Meeting-held-on-11-April-2025.pdf
  162. https://www.astrazeneca.com/content/dam/az/Investor_Relations/corporate-governance/AZ_PLC_Board_Committee_Membership.pdf
  163. https://www.astrazeneca.com/content/dam/az/Investor_Relations/corporate-governance/Board-Inclusion-and-Diversity-Policy.pdf
  164. https://www.opensecrets.org/federal-lobbying/clients/summary?id=D000043112
  165. https://www.opensecrets.org/federal-lobbying/clients/lobbyists?cycle=2025&id=D000043112
  166. https://law.justia.com/cases/federal/appellate-courts/ca3/24-1819/24-1819-2025-05-08.html
  167. https://www.astrazeneca-us.com/media/press-releases/2025/astrazeneca-announces-historic-agreement-with-us-government-to-lower-the-cost-of-medicines-for-american-patients.html
  168. https://www.astrazeneca-us.com/sustainability/Corporate-transparency/political-contributions.html
  169. https://www.opensecrets.org/political-action-committees-pacs/astrazeneca-pharmaceuticals/C00279455/summary/2024
  170. https://www.lobbyfacts.eu/datacard/astrazeneca
  171. https://sciencebusiness.net/viewpoint/life-sciences/viewpoint-eu-pharma-reform-will-stifle-innovation-says-astrazenecas-stefan
  172. https://www.theguardian.com/environment/2024/oct/25/astrazeneca-uk-jobs-biodiversity-drug-levy
  173. https://accesstomedicinefoundation.org/company/astrazeneca-plc
  174. https://pmc.ncbi.nlm.nih.gov/articles/PMC8704023/
  175. https://www.cnn.com/2021/02/17/europe/uk-astrazeneca-vaccine-contract-details-intl
  176. https://ec.europa.eu/commission/presscorner/detail/en/ip_21_302
  177. https://www.astrazeneca.com/media-centre/press-releases/2020/astrazeneca-to-supply-europe-with-up-to-400-million-doses-of-oxford-universitys-vaccine-at-no-profit.html
  178. https://www.politico.eu/article/the-key-differences-between-the-eu-and-uk-astrazeneca-contracts/
  179. https://www.emergentbiosolutions.com/press/news-release-details-emergent-biosolutions-signs-agreement-astrazeneca-expand/
  180. https://www.astrazeneca.com/media-centre/press-releases/2021/us-supply-agreement-for-additional-azd7442-doses.html
  181. https://www.usaspending.gov/award/CONT_AWD_W15QKN21C0003_9700_-NONE-_-NONE-
  182. https://www.forbes.com/sites/ritanumerof/2025/10/17/what-pfizer-and-astrazenecas-deals-with-the-trump-administration-mean-for-pharma/
  183. https://european-biotechnology.com/latest-news/astrazeneca-agrees-to-mfn-price-reductions-with-us-government/
  184. https://www.astrazeneca.com/sustainability/partnerships-and-alliances.html
  185. https://www.ukri.org/who-we-are/how-we-are-doing/research-outcomes-and-impact/mrc/the-story-behind-the-oxford-astrazeneca-covid-19-vaccine-success/
  186. https://pmc.ncbi.nlm.nih.gov/articles/PMC9465517/
  187. https://www.nature.com/articles/s41591-020-01179-4
  188. https://www.astrazeneca.com/media-centre/press-releases/2020/azd1222hlr.html
  189. https://www.nih.gov/news-events/news-releases/phase-3-clinical-testing-us-astrazeneca-covid-19-vaccine-candidate-begins
  190. https://www.nejm.org/doi/full/10.1056/NEJMoa2105290
  191. https://www.ema.europa.eu/en/human-regulatory-overview/public-health-threats/coronavirus-disease-covid-19/covid-19-medicines/safety-covid-19-vaccines
  192. https://www.nature.com/articles/s41467-022-33378-7
  193. https://pmc.ncbi.nlm.nih.gov/articles/PMC9965204/
  194. https://www.astrazeneca.com/media-centre/press-releases/2020/astrazenecas-covid-19-vaccine-authorised-in-uk.html
  195. https://www.who.int/news/item/15-02-2021-who-lists-two-additional-covid-19-vaccines-for-emergency-use-and-covax-roll-out
  196. https://www.astrazeneca.com/media-centre/press-releases/2021/astrazeneca-advances-mass-global-rollout-of-covid-19-vaccine-through-covax.html
  197. https://www.astrazeneca.com/our-therapy-areas/vaccines-and-immune-therapies/covid-19.html
  198. https://www.ox.ac.uk/news/2022-07-15-oxford-vaccine-saved-most-lives-its-first-year-rollout
  199. https://www.airfinity.com/articles/astrazeneca-and-pfizer-biontech-saved-over-12-million-lives-in-the-first
  200. https://www.clinicaltrialsarena.com/news/astrazeneca-vaxzevria-effective-variants/
  201. https://www.astrazeneca.com/media-centre/medical-releases/vaxzevria-73-effective-at-preventing-omicron-related-infections-after-fourth-dose-according-to-real-world-evidence-study-in-thailand.html
  202. https://www.astrazeneca.com/media-centre/medical-releases/vaxzevria-highly-effective-at-preventing-covid-19-severe-outcomes-and-death.html
  203. https://ncirs.org.au/how-common-are-severe-side-effects-covid-vaccines-and-how-are-they-detected
  204. https://www.who.int/news-room/feature-stories/detail/the-oxford-astrazeneca-covid-19-vaccine-what-you-need-to-know
  205. https://www.sciencedirect.com/science/article/pii/S0264410X24001270
  206. https://www.astrazeneca.com/media-centre/press-releases/2022/vaxzevria-receives-full-marketing-authorisation-in-the-eu-for-the-prevention-of-covid-19.html
  207. https://www.who.int/news/item/16-04-2021-global-advisory-committee-on-vaccine-safety-%28gacvs%29-review-of-latest-evidence-of-rare-adverse-blood-coagulation-events-with-astrazeneca-covid-19-vaccine-%28vaxzevria-and-covishield%29
  208. https://www.telegraph.co.uk/news/2024/04/28/astrazeneca-admits-covid-vaccine-causes-rare-side-effect/
  209. https://www.bmj.com/content/380/bmj.p725
  210. https://ann-clinmicrob.biomedcentral.com/articles/10.1186/s12941-023-00594-y
  211. https://pmc.ncbi.nlm.nih.gov/articles/PMC8548286/
  212. https://www.justice.gov/archives/opa/pr/pharmaceutical-giant-astrazeneca-pay-520-million-label-drug-marketing
  213. https://abcnews.go.com/Politics/Health/astrazeneca-pay-520-million-illegally-marketing-seroquel-schizophrenia/story?id=10488647
  214. https://www.bmj.com/content/340/bmj.c2380
  215. https://www.atg.wa.gov/news/news-releases/states-reach-record-685-million-settlement-seroquel-maker
  216. https://www.texasattorneygeneral.gov/news/releases/ag-paxton-recovers-110-million-texas-medicaid-fraud-settlements
  217. https://violationtracker.goodjobsfirst.org/parent/astrazeneca
  218. https://litigationtracker.law.georgetown.edu/litigation/astrazeneca-pharmaceuticals-lp-et-al-v-becerra-et-al/
  219. https://www.bigmoleculewatch.com/2025/05/15/third-circuit-affirms-rejection-of-astrazenecas-challenges-to-ira-drug-price-negotiation-program/
  220. https://www.thepharmaletter.com/pharmaceutical/astrazeneca-escalates-drug-pricing-fight-to-supreme-court
  221. https://www.reuters.com/legal/government/astrazeneca-agrees-51-million-settlement-seroquel-antitrust-class-action-2025-05-30/
  222. https://bmjgroup.com/bmj-finds-inaccuracies-in-key-studies-for-astrazenecas-blockbuster-heart-drug-ticagrelor/
  223. https://www.fiercepharma.com/pharma/astrazeneca-faces-new-allegations-over-trial-data-blood-thinner-brilinta-bmj
  224. https://www.sciencedaily.com/releases/2025/06/250621233811.htm
  225. https://www.news-medical.net/news/20241211/Controversy-surrounds-landmark-anti-platelet-drug-trial.aspx
  226. https://interhospi.com/bmj-investigation-reveals-astrazenecas-billion-dollar-heart-drug-built-on-flawed-data/
  227. https://www.nytimes.com/2021/03/23/business/astrazeneca-vaccine-questions.html
  228. https://www.bmj.com/content/372/bmj.n807
  229. https://ashpublications.org/ashclinicalnews/news/5592/AstraZeneca-COVID-19-Vaccine-Data-Highlight-Safety
  230. https://www.sec.gov/files/litigation/admin/2016/34-78730-s.pdf
  231. https://www.reuters.com/article/business/astrazeneca-to-pay-552-million-to-resolve-sec-foreign-bribery-case-idUSKCN1152U8/
  232. https://fcpaprofessor.com/astrazeneca-coughs-5-5-million-resolve-fcpa-action/
  233. https://www.theguardian.com/business/2024/nov/05/astrazeneca-shares-tumble-reports-china-unit-linked-insurance-fraud
  234. https://www.caixinglobal.com/2025-05-01/astrazeneca-faces-intensified-probe-in-china-as-tax-evasion-amount-grows-102315818.html
  235. https://www.astrazeneca.com/media-centre/press-releases/2024/astrazeneca-china-president-currently-under-investigation.html
  236. https://www.fiercepharma.com/pharma/astrazeneca-stock-tanks-over-fears-expanding-china-fraud-probe
  237. https://www.astrazeneca.com/content/dam/az/PDF/Sustainability/Ethics%2520and%2520transparency.pdf
  238. https://www.bbc.com/news/health-20468396
Add your contribution
Related Hubs
User Avatar
No comments yet.